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DESIGN AND SYNTHESIS OF ANTITHROMBOTIC
LIPOSOMAL PROTEIN CONJUGATE

HAILONG ZHANG

ABSTRACT
Recent advances in the molecular bases of haemostasis have highlighted that
endothelial thrombomodulin (TM) plays a critical role in local haemostasis by binding
thrombin and subsequently converting protein C to its active form (APC). In addition, the
binding of thrombin to TM drastically alters the thrombin’s procoagulant activities to
anticoagulant activities. The lipid bilayer in which it resides serves as an essential
‘cofactor’, locally concentrating and coordinating the appropriate alignment of reacting
cofactors and substrates for protein C activation. On the other hand, liposomes have been
extensively studied as cell membrane model as well as carrier for delivering certain
vaccines, enzymes, drugs, or genes. In this study, antithrombotic liposomal TM conjugate
was design and developed by combination of antithrombotic membrane protein TM into
liposome through recombinant and bioorthogonal conjugation techniques, which
providing a rational strategy for generating novel and potential antithrombotic agent.
Namely, the liposomal TM conjugate mimics the native endothelial antithrombotic

v

mechanism of both TM and lipid components and thus is more forceful than current
antithrombotic agent.
First, an efficient and chemoselective liposome surface functionalization method
was developed based on Staudinger ligation, in which a model compound carbohydrate
derivative carrying a spacer with azide was conjugated onto the surface of preformed
liposomes carrying a terminal triphenylosphine in PBS buffer (pH 7.4) and at room
temperature.
Second, recombinant TM containing the EGF-like domains 456 with an
azidohomoalaine at the C-terminal has been expressed and incorporated into liposome to
form antithrombotic liposomal TM conjugate via Staudinger ligation. In addition, another
chemically selective liposomal surface functionalization method for antithrombotic
liposomal TM conjugated has been developed based on copper-free click chemistry,
which provides an alternative approach to improving reaction efficiency and stability and
represents an optimal platform for exploring membrane protein’s activity of TM.
In addition, chemically selective liposomal surface functionalization and
liposomal microarray fabrication using azide-reactive liposomes has been developed and
confirmed by fluorescence imaging, fluorescent dye releasing kinetics, and AFM
techniques. The azide-reactive liposome provides a facile strategy for membrane-mimetic
glyco-array fabrication, which may find important biological and biomedical applications
such as studying carbohydrate–protein interactions and toxin and antibody screening.
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CHAPTER I
INTRODUCTION

1.1. Thrombosis and endothelial thrombomodulin (TM)
Thromboembolic

diseases

such

as

myocardial

infarction,

stroke,

and

thromboembolism are major public health problems with significant mortality and
morbidity in the United States [1]. It has been considered that all these diseases are
primarily disorder of platelet function and the coagulation. In the past decades,
antiplatelet agents such as aspirin and ticlopidine and anticoagulant agents such as
heparin and warfarin have been established and provided remarkable achievements in the
treatment of thromboembolic diseases. However, these drugs have considerable
limitations. In particular, the complications associated with bleeding represent a major
drawback. Heparin and warfarin require laboratory monitoring, which are inconvenient to
both patients and physicians and are costly. Furthermore, no beneficial effects in
preventing restenosis after revascularization procedures have yet been obtained with the
established antithrombotic agents.
Recent understanding of haemostasis in the molecular bases has highlighted new
targets for novel antithrombotic agent design. For example, antithrombotics aiming at

1

inactivating thrombin, inhibiting thrombin generation, inhibiting fibrin formation,
inactivating coagulation cascade factors, destroying fibrin and interrupting platelet
activity have been investigated widely [2]. In particular, selective inhibitors of thrombin
and factor Xa, and components of the anticoagulant protein C system (recombinant
activated human protein C or human soluble thrombomodulin) have been extensively
studied. Some of these agents have had promising results in Phase III studies but still
with limitations above. Given the limitations of the current antithrombotic agents,
development of new antithrombotics with improved antithrombotic activity and reduction
of unwanted bleeding and easier patient management is highly demanded.

1.1.1 Endothelial TM Plays a Central Role in Local Haemostasis
Thrombosis results from a failure of haemostatic balance, which is normally
maintained by a complex series of coagulation reactions that involve both systemic and
local factors [3]. The endothelium contributes to local haemostatic balance by producing
thrombomodulin (TM), which functions as an essential cofactor for the activation of
anticoagulant protein [4]. TM modulates the activity of thrombin from a procoagulant to
an anticoagulant protease [5]. To date, TM not only is a natural anticoagulant but also
functions in anti-inflammatory (Figure 1.1) [6]. The anticoagulant function of TM was
performed through protein C anticoagulant systems. In the protein C pathway, protein C
will be activated to form activated protein C (APC) by thrombin, in which the speed of
activation is very slow. After binding with TM on the surface of endothelial membrane,
thrombin immediately enhances protein C activation by 1000 fold. On the one hand, APC
produced in the pathway performed anticoagulant by inhibition of thrombin. Briefly,
2

APC binds protein S to form new complex after dissociating from endothelial cell protein
C receptor (EPCR), which prevents thrombin generation by destroying factor FVa and
FVIIIa. At same time, the inhibition of thrombin induces an indirect inflammation by
preventing activation of protease-activated receptor (PAR)-1. On the other hand, APCEPCR complex anti-inflammatory effects via direct modulation of PAR-1[7].

Figure 1.1 Crosstalk Between Inflammation and Coagulation. Thrombin acts to form a
positive feedback loop that augments coagulation and inflammation. In a negative
feedback loop, the thrombin-TM complex activates protein C and downregulates
coagulation and inflammation. APC, in tandem with its cofactor protein S, inactivates
FVa and FVIIIa. In addition, the APC-EPCR complex induces anti-inflammatory effects
through PARs. Therefore, thrombin, TM, and protein C-EPCR play pivotal roles in the
crosstalk that occurs between inflammation and coagulation. Reproduced from [6]

1.1.2 TM Structure and Function
3

As a natural anticoagulant protein, human TM, consisting of 557 amino acids, is
mostly expressed on the surface of endothelium cell membranes and is structurally
divided into five consecutive domain from amino terminal (Figure 1.2) [5]. C-type lectin
domain, from N-terminal of TM, is responsible for mediating anti-inflammatory activities
[8]. Adjacent to the lectin like domain is the epidermal growth factor (EGF)-like domain
consisting of six repeat, which plays a key role in protein C activation and anticoagulant
activity of TM. Although there remains unknown function for the first two EGF-like
repeats (1-2), another three EGF-like repeats (4-6) have been studied very extensively
and are responsible for whole activation of protein C [9]. Actually, EGF-like repeats 5-6
do not involve protein C activation by itself, but are necessary for binding thrombin to
TM via thrombin’s anion-binding exosite I. Differently, EGF like repeats 3-6 are
responsible for activation of thrombin activatable fibrinolysis inhibitor (TAFI) [10]. After
EGF like domain, there is O-linked glycosylation domain composing of serine/threonine,
in which chondroitin sulfate is attached to TM to enhance protein C activation of TM by
strengthening the thrombin-TM binding at anion-binding exosite 2 of Thrombin [11].
Next, a membrane spanning region consisting of 23 hydrophobic amino acids is linked to
o-glycosylation domain. Finally, a short cytoplasmic domain containing a free cysteine is
attached to C terminal in which cysteine may be responsible for meditation of
multimerization to TM [12].

4

Figure 1.2 TM Structure and the Model of Protein C Activation Complex. Thrombin
binding to thrombomodulin involves anionbinding exosite 1 on thrombin and EGF
domains 4 to 6 on thrombomodulin. A chondroitin sulfate moiety on thrombomodulin
increases the affinity for thrombin by binding anion-binding exosite 2 on thrombin. The
activation of protein C to APC by the thrombin-thrombomodulin complex is enhanced by
binding to EPCR. Reproduced from [13].

1.1.3 Current Research on Exploring on the Therapeutic Applications of
Recombinant TM
It has been known that thromboembolic disorders have been found to result from
relative deficiency of TM [14] or protein C [15], and homozygous deficiency of TM has
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even been shown to confer lethality in mice [16]. The conversion of protein C to APC
may be impaired during sepsis because of the down-regulation of TM by inflammatory
cytokines [17]. The decrease in TM expression is associated with a local inflammatory
response [18], and transcription of the TM gene is known to be negatively regulated by
inflammatory cytokines such as tumor necrosis factor (TNF)-α or interleukin-1 [19]. An
alternative possibility is that TM may be shed from the endothelial surface by proteases
produced by activated leukocytes [20]. It has been demonstrated that local overexpression of TM through adenoviral gene transfer can prevent thrombosis in an animal
model [21]. However, gene therapies currently are not suitable to manage acute
cardiovascular conditions.
Recent studies have shown that recombinant human soluble TM (rhsTM, the extra
cellular portion of TM) has a long biological half-life in the absence of significant
systemic coagulation and produces dose-dependent anticoagulant and antithrombotic
effects in both rodents and primates [22-25]. In tissue factor-infused monkeys, rhsTM
pretreatment decreases the concentration of thrombin–antithrombin complexes in a dosedependent manner. Recombinant soluble TM is anticoagulant to various degrees in
normal and protein C-depleted plasma [26]. A most recent study with a primate model
demonstrated the antithrombotic effects of rhsTM were largely intact in the presence of
protein C blocking antibody [27]. This study showed that pharmacological doses of
rhsTM directly inhibited the prothrombotic response (thrombin generation) and
upregulation of antithrombotic system (APC generation). This is in contrast to the
conclusions of previous studies, which attributed the antithrombotic effects of rhsTM
primarily to APC generation [28]. Therefore, rhsTM might exert anticoagulant effects by
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at least two mechanisms: (1) directly, via direct thrombin inhibition and (2) indirectly, via
supporting the thrombin/thrombomodulin-catalyzed local activation of protein C at the
site of thrombin generation.

1.1.4 Lipid Membranes Play a Pivotal Role in Regulating Blood Coagulation
Reactions
Both procoagulant and anticoagulant reactions occur at a physiologically
significant rate only when the respective enzymes form multicomponent complexes on
lipid membrane surfaces [29]. It has been observed that lipid vesicles containing
negatively charged phospholipids, especially phosphatidylserine (PS), markedly enhance
the rate of activation of procoagulant and anticoagulant enzymes [30, 31]. TM is a
membrane protein of endothelium. The lipid bilayer in which it resides serves as an
essential ‘cofactor’, locally concentrating and coordinating the appropriate alignment of
reacting cofactors and substrates for protein C activation (Figure 1B). In concert with
TM, the lipid membrane accelerates protein C activation and subsequently optimizes
APC anticoagulant activity. Esmon et al. had demonstrated that TM incorporated into
lipid vesicles resulted in substantially enhanced protein C activation [32]. The Km for
protein C obtained with TM incorporated into lipid vesicles is very similar to that
obtained on the endothelial cell surface. Studies also suggested that protein C prefers
binding onto lipid membrane containing both phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) [33, 34]. On the other hand, efficient inactivation of
Factor Va by APC requires the presence of negatively charged phospholipids, with
phosphatidylserine (PS) being the most potent stimulator of the APC cleavage of Factor
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Va [31]. In addition, incorporation of phosphatidylethanolamine (PE) into the
phospholipid membrane has been found to enhance the inactivation of Factor Va by APC
[35]. Therefore, lipid membrane is necessary to preserve TM’s activity and the lipid
membrane recognition is necessary for both protein C activation and Factor Va
inactivation and shares many properties in common with the endothelial cell surface.

1. 2 Liposomes as Drug Delivery Vehicles
1.2.1 Liposomes
Liposomes, artificial microscopic and self-closed vesicles consisting of bilayer
phospholipids membrane as model of biological cell membrane, have been studied
extensively during the past few decades as drug delivery systems with great potential.
Lipids as parts of natural membranes in live organism exit low immunogenicity and
toxicity, good biocompatibility and biodegradability [36] and has been considered as a
useful tool in genetic engineering and diagnostic techniques [37]. Additionally, due to
their structure, chemical composition and colloidal size, liposomes are easily prepared as
controlled size from microscale to nanoscale and surface functionalization through
chemical biology with carbohydrate, peptide and protein [38-40].
Normally, liposomes are classified according to size and lamellarity. Small
unilamellar vesicles (SUV) consist of a single lipid bilayer with 25-100 nm in size; large
unilamellar vesicles (LUV) shows a diameter of 100-400 nm; multilamellar vesicles
(MLV) consist of two or more concentric bilayers with a size range of 200 nm to several
microns; multivesicular vesicles (MVV) usually have multicompartmental structure with
more than 1 micrometer in size [41]. As cell-like compartments, liposomes’ size and
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lamellarity with lipid composition play a vital role in modeling cell properties like the
fluidity, permeability, stability [42]. In turn, liposomes could meet specific needs since
the size, lamellarity and composition can be controlled and prepared by requirement.
Since liposome has been recognized 40 years ago, several generation of liposome
based drug delivery systems have been developed to overcome drawbacks such as short
life time or non-targeting and diverse pharmaceutical criteria (Figure 1.3) [43].

Figure 1.3 Evolution of Liposomes. A. Early traditional phospholipids ‘plain’ liposomes
with water soluble drug in interior (a) or membrane (b). B. Antibody-targeted
immunoliposome with antibody covalently coupled (c) or hydrophobically anchored (d)
C. Long-circulating liposome grafted with a protective polymer (e) from opsonizing
proteins (f). D. Long-circulating immunoliposome simultaneously bearing both protective
polymer and antibody in the surface (g) or the chain end (h). E. New-generation
liposome, the surface of which can be modified (separately or simultaneously) by
different ways: protective polymer (i&o), antibody (j), diagnostic label (k), charged
lipids (l&n), DNA (m), peptide (p), viral components (q), magnetic particles (r), gold or
silver particles (s). traditional liposomes. Reproduced from [43].

Early traditional liposomes are mainly comprised of natural phospholipids or
lipids such as dipalmitoyl phosphatidil choline (DPPC, PC or egg phosphcholine),
monosialoganglioside. As the first generation of liposome, although early traditional
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liposomes have attracted a lot of attention in basic science research [44], they are limited
to further application in pharmaceutical industry and clinical setting due to poor stability,
short half-time and toxicity in some systems [45-47]. Many attempts have been made to
remove those drawbacks. For example, cholesterol was added to bilayer mixture to
stabilize the structure of bilayer membrane [48]; liposome composed of egg lecithin was
prepared by insertion of negative or positive charges to improve drug entrapment
efficiency [49]; liposomes with different size range have been made to explore the effect
of morphology of liposome on halt-time of liposome in the systemic circulation [50].
However, the major problems such as fast elimination and non-targeting still remain
unresolved.

1.2.2 Stealth Liposomes
First breakthrough in the liposome development is stealth liposome or longcirculating liposome. Stealth liposome strategy was achieved simply by coating the
surface of liposome with a hydrophilic and biocompatible polymer-poly ethylene glycol
(PEG). PEG provides a stereic barrier that prevents liposome aggregation and opsonizing
proteins (Figure 1.3 C) [51]. Many other hydrophilic polymers such as chitosan [52], silkfibroin [53], and polyvinyl alcohol (PVA) [54] have been tried to increase half-time of
liposome and reduce toxicity. Although those hydrophilic polymers could meet
biodegradability, nontoxicity and lower immunogenicity, PEG still keep the gold
standard in protecting liposome and increasing circulation time. Vaccines or anticancer
therapeutics to non-viral gene therapy vectors sequesters part of the solvent, in which
they freely float into their interior. In the case of one bilayer encapsulating the aqueous
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core one speaks either of small or large unilamellar vesicles while in the case of many
concentric bilayers one defines large multilamellar vesicles. All of which can be well
controlled by preparation methods, liposomes exhibit several properties which may be
useful in various applications. The most important properties are colloidal size, i.e. rather
uniform particle size distributions in the range from 20 nm to 10 μm, and special
membrane and surface characteristics. They include bilayer phase behavior, its
mechanical properties and permeability, charge density, presence of surface bound or
grafted polymers, or attachment of special ligands, respectively. Additionally, due to their
amphiphilic character, liposomes are a powerful solubilizing system for a wide range of
compounds. In addition to these physico-chemical properties, liposomes exhibit many
special biological characteristics, including (specific) interactions with biological
membranes and various cells [55].

1.2.3 Targeted Liposome
The further development of liposome involves increasing liposomal drug
accumulation in the desired tissues and organs, in other words, specific targeting of
liposome based systems should be addressed (Figure 1.3 B, D&E). Overcoming the
biological barriers between administration and the site of action of drug or gene is
becoming increasingly important for the development of better and safer medicines.
Small organic molecule-based drugs often suffer from poor bioavailability problems,
such as limited water solubility and/or poor membrane permeability. Peptide, protein, or
DNA-based biomacromolecules are even more challenging to develop safe and efficient
drug products due to the size and poor biological stability as well as immunogenicity
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problems [57]. Targeted liposome increases noticeably the local drug concentration in the
ideal tissue or cells without harmful side effect on healthy cells or/and systemic side
effect [58-60]. Different types of targeting moieties such antibodies, peptide,
glycoprotein, oligopeptide, polysaccharide, growth factors, folic acid, carbohydrate,
receptors, and peptides have been extensively explored to conjugate liposome to
overcome these limitations in the past decades [61-64].

1.3 Current Methods for Liposome Surface Modification
Liposomes as mimics of cell membrane have attracted much attention.
Conjugation different ligands such as proteins, peptides and drugs to liposomes has been
studied extensively in numerous applications. A number of conjugation methods have
been developed for liposome surface functionalization and are described in the following.

1.3.1 Direct Liposome Formation with Ligands
To most of small ligands, surface modification of liposome through direct
liposome formation is common method. This strategy involves the initial synthesis of the
key lipid-ligand conjugate, followed by formulation of the liposome with all lipid
components. In this direct liposome formation method, around 50% of total ligands
inevitably are facing the interior of liposome and thus become unavailable for their
intended interaction with their target molecules. This approach is well suited for ligands
that are cheap and in large quantities, such as saccharides [65] and vitamins [66].
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1.3.2 Post-Insertion Approach
Another method for liposome surface modification was developed to overcome
problems in surface modification through direct liposome formation. In this approach,
liposome was prepared firstly, and then functionalized ligands with lipid tailor will
incorporate into performed liposome. Normally, targeted ligands will be covalenty
attached with lipids and then dissolved into buffer to form micelles. Next, micelles
containing ligands will mix with performed liposome to allow ligands incorporate into
performed liposome by fusion. Lipid-ligand conjugates normally have limited solubility
and stability in solvent, or are incompatible with various stages of manufacture. The
advantages of this approach for liposome surface modification include reducing ligands
amounts, noncovalent and reversible incorporation and make it suitable to antibody [67],
protein [68] and peptides [69] incorporation into the liposome surface. On the other hand,
this approach suffers from low incorporation efficiency and limited solubility and
stability of ligands conjugates with lipid in solvent, as a result, limits its applications.

1.3.3 Post-Functionalization Approach
Chemical modification methods, namely post-functionalization, which in most
cases involve the coupling of biomolecules to the surface of preformed vesicles that carry
functionalized (phospho) lipid anchors, have been developed [70]. So far, variable
coupling methods for post functionalization such amide or thiol-maleimide coupling as
well as by imine or hydrazone linkage have been achieved. Below each coupling reaction
for post liposome surface functionalization are described in detail (Figure 1.4).
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Figure 1.4 Schematic Illustration of the Various Coupling Methods that have been
Developed in order to Post-Functionalized Liposomes: a Amine functionalization, b
carboxylic

acid

functionalization,

c

aldehyde

functionalization,

d

hydrazine

functionalization, e maleimide functionalization, f thiol functionalization, g thiol
functionalization (disulfide bond formation), h bromoacetyl functionalization, i cysteine
functionalization, j cyanur functionalization, k p-nitrophenylcarbonyl functionalization, l
alkyne functionalization, m triphenylosphine functionalization. Reproduced from [71].

1.3.3.1 Traditional Covalent Conjugation
Linkages containing amide bonds
The amide bond, generally represented as RC(O)NH2, is very stable and widely
used for surface modification by bioconjugation and becomes one of earliest methods to
functionalize performed liposome. This linkage could be performed by coupling ligands
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to amine functionalized liposomes or coupling ligands to carboxylic aicd modified
liposomes. Since liposome is kind of water solution, water soluble carbodiimides, such as
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride [EDC] was used to allow
for an aqueous conjugation reaction. And N-hydroxysulfosuccinimide [Sulfo-NHS] is
used to form a stable intermediate (NHS ester derivatives) and followed by formation of
amide bonds with high efficiency.
Another poplar approach through linkage containing amine bonds is to exploit the
reaction between aldehyde and hydrazide group (Figure 1.4d). Normally, hydrazide will
be incorporated into liposome to attain hydrazide functionalized liposome which will
react with aldehyde group in antibody or protein. This coupling is specially suited for
preparation of antibody liposome conjugates [72]. Chua et al used this approach to attach
immunoglobulin to liposome surface [73]. In this study, carbohydrate groups in the heavy
chain of the immunoglobulin were oxidation to afford aldehyde in the help of galactose
oxidase or sodium periodate. Finally, immunoglobulin was immobilized onto the surface
of liposome by formation of amide bonds between aldehyde in the immunoglobulin and
hydrazide in the surface of liposome.
Additional amide bonds could be formed between p-nitrophenylcarbonyl group
and primary amines (Figure 1.4 k). This method allows directly conjugation of antibodies
into the liposome without additional modification. Torchilin et al successfully attached
several proteins such as avidin, antimyosin antibody 2G4, wheat germ agglutinin and
concanavalin into the liposome surface via a stable and non-toxic amide bond [74].
However, one main drawback of this approach lies in usage of bifunctional p-
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nitrophenylcarbonyl because this bifunctional molecule offers a possibility of crosslinking.
Linkages containg thioethers
Considering thiol is another common group in the protein, the reaction of
thioethers between protein and thiol-reactive liposome has been studied well for liposome
surface modification. The thiol-reactive functional groups are kind of ankylating reagents
including include iodoacetamides (Figure 1.5A), maleimides (Figure 1.5B), and
disulfides (Figure 1.5C). Iodoacetamides easily react with thiols group in the proteins
peptides and antibodies via formation of thioethers. Normally, they are more likely
reactive with thiol group in the cysteine but may also react with ones in the tyrosine or
histidine. For instance, Frisch et al. has successfully attached peptides containing cysteine
to the surface of liposome functionalized with bromoacetyl [75]. This coupling reaction
was performed at pH 9.0 and done in one hour. The reaction condition developed here
did not alter the integrity of liposome and are harmless to liposome surface modification.
The maleimide reaction is most effective and common approach in bioconjugation
chemistry for surface modification due its high efficiency and selectivity with
minimization of side reactions [Figure 1.5B]. This approach involves reaction of thiols in
the proteins or peptides and double bond in the maleimides to form a stable thioether
bond, allowing conjugation proteins or peptides covalently into liposome surface. A
number of researches have been focused on liposome surface modification by maleimides
reactions. For example, Garnier et al. recently immobilized the Annexin-A5 protein onto
liposome surface modified with maleimides [76]. Another case is the selective
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conjugation of thiolated OX26 monoclonal antibodies to DSPE-PEG-maleimide
functionalized liposome [77].
Compared to iodoacetamides and maleimide reaction, disulfides reaction is freely
reversible and thiol specific. The new disulfide bond was formed through a thiol-disulfide
exchange and therefore improves resistant to hydrolysis. Gyongyossy-Issa et al used this
approach to successfully conjugate RGD-motif-containing peptide into liposomes by a
thiol-disulfide exchange and provides a choice for target drug delivery [78]

Figure 1.5 Bioconjugation via Thioethers or Disulfides. Reaction of a thiolate with (A) a
haloacetamide, (B) a maleimide, and (C) a disulfide linkages. Reproduced from [79]

Containing carbon–nitrogen double Bonds
Bioconjugation via carbon–nitrogen double bonds by which ligands can be
incorporated into liposome surface in physiological condition has received much
attention. In this approach, nitrogen bases react with aldehydes and ketones to afford
carbon-double bonds including hydrazones (C=N–N) and oximes (C=N–O). Nitrogen
and Oxygen in the terminal of carbon-double bonds make it more stable compared to
regular products of amines with aldehydes or ketones. A number of researches have been
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conducted on liposome functionalization by antibodies or proteins by this strategy. In this
strategy, aldehyde could be from ligands or performed liposome. Bonnet et al.
successfully incorporate hydrazino-derivatized ligands to aldehyde functionalized
liposomes via formation of hydrazone. In this study, functionalized anchor lipid
(aldehyde functionalized ether lipid di-O-hexadecyl-rac-glyceraldehyde) was ynthesized
firstly and used for liposome preparation; next, lysosome-associated membrane protein
(LAMP) was modified by N,N,N-tri(tert-butyloxycarbonyl)-hydrazino acetic acid and
then incubated into aldehyde functionalized liposome to afford LAMP liposome
conjugate. In contrast, Torchilin et al.chose amine functionalized liposome for
conjugation of rabbit anticanine cardiac myosin antibodies [80]. In this experiment,
glutaraldehyde and dimethyl suberimidate are utilized for conjugation via formation of
oximes.

1.3.3.2 Bioorthogonal Conjugation
To date, most of available conjugation methods are non-specific and less selective
interaction, and also suffer from low efficiency and toxicity to living organism. As a
result, there are less reliable and safe for living systems. Fortunately, a number of
bioorthogonal reactions have been developed. Compared to traditional chemical methods,
these bioorthogonal reactions have shown excellent biocompatibility and selectivity in
living systems. Each of bioorthogonal reactions used for liposome surface modification
will be discussed in detail.
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Native chemical ligation
Native chemical ligation is one of most widely used methods for chemical
biology. This strategy was developed by Dawson et al to ligate large unprotected peptide
fragments [81]. In this reaction, two unprotected peptide segments by the reaction of a αthioester with a cysteine-peptide can be connected at the physiological condition (Figure
1.6). Numerous studies have been conducted on national chemical ligation and its
applications such as protein synthesis, in vivo imagine, surface modification and protein
array [82].

Figure 1.6 Principle of Native Chemical Ligation. Reproduced from [82]
Considering its chemoselectivity and high efficiency in physiological condition,
Reulen et al. first introduced this ligation to liposome surface modification [83]. In this
study, anchor lipid (DSPE-PEG-Cysteine) for native chemical ligation has been firstly
synthesized and then was allowed to preparation of liposome containing anchor lipid.
Next, Enhanced yellow fluorescent protein (EYFP) and a collagen-binding protein
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domain (CNA35) modified with odium 2-mercaptoethanesulfonate (MESNA) were
chosen to perform native chemical ligation. After incubation in HEPES buffer for 48h,
cysteine functionalized liposome has been successfully modified by EYFP and CNA35.
The strategy developed here provides an alternative method for liposome surface
modification.

Staudinger ligation
The Staudinger ligation, in which an azide and triphenylosphine selectively react
to form an amide, has been used for chemical selective modification of recombinant
protein under native condition [84]. Recently, Staudinger ligation has been successfully
performed in living animals without physiological harm, suggesting the potential for
applications in cell surface functionalization [85]. Particularly, the reaction is known to
occur in high yield at room temperature in aqueous solvents and without any catalyst, and
is compatible with the unprotected functional groups of wide range of biomolecules. We
have developed an efficient and chemically selective liposome surface functionalization
with lactose as model carbohydrate through Staudinger ligation [38] (Figure 1.7). The
high specificity and high yield as well as biocompatible reaction condition natures of the
Staudinger ligation approach make it an attractive alternative to all current protocols for
liposome surface functionalization.
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Figure 1.7 Schematic Illustration of Liposome Surface Glyco-Functionalization through
Staudinger Ligation. Reproduced from [38]

Click chemistry
As one of the most popular reactions for bioconjugation techniques in chemical
biology, Click chemistry was developed by K. Barry Sharpless based on the 1, 3-dipolar
cycloaddition reaction between azides and acetylenes to yield triazoles in 2001 [86]. In
the reaction, an organic azide reacts with an alkyne to form a stable triazole ring under
help of Cu (I) in aqueous conditions with high efficiency. Bothe of reactants-azide and
alkyne are very inert and orthogonal to other chemical functionalities which offer this
reaction high selectivity. Therefore, Click chemistry is extremely valuable in chemical
biology by proving an excellent technology for bioconjugation and has attracted much
attention in many areas such as protein modification, microarray, cell imaging and
peptides synthesis. Hassane et al. successfully expanded this strategy into liposome
surface

functionalization

[87].

First,
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anchor

lipid

N-[2-(2-(2-(2-(2,3-

bis(hexadecyloxy)propoxy)ethoxy)ethoxy)-ethoxy)ethyl]hex-5-ynamide was synthesized
in which alkyne group was inserted into the terminal of lipid for conjugation. Then,
liposome with incorporation of anchor lipid above were prepared and followed to
incubate with an azido-modified mannose ligand for 24 h. After evaluation of mannose
onto the surface of liposome, this in situ surface modification showed around 25% yield.
Another example for liposome surface modification was adopted by Cavalli et al. [88]. In
this study, Alkyne functionality was inserted into the liposome surface by incorporating
alkyne functionalized 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). A single
amino acid α-azido-modified lysine was chosen and mixed together with alkyne
functionalized liposome to perform this coupling reaction under help of Cu (I) (Figure
1.8). Unfortunately, due to introduction of cooper as a catalyst, this strategy limited its
wide application in living organism since cooper is heavy metal and could be toxic to
living systems.

Figure 1.8 Schematic Representation of the General Approach for the Chemical
Modification of a Liposome Surface by Peptides via Copper (I)-Mediated [3+2] AzideAlkyne Cycloaddition. Reproduced from [88]
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1.4 Incorporation of Unnatural Amino Acid for Protein Engineering through
Synthetic Biology
Unnatural amino acids (UAAs), unlike a standard set of 20 amino acids, are not
basic blocks for building living organism in the earth but still represent an enormous
amount of diverse structural elements and provide a great potential to build a new protein
with novel function or enhance properties to meet numerous needs of life. Sometimes
UAAs other than basic amino acids plays a vital role in biology activity. For example, as
an inhibitory neurotransmitter, gamma-amino butyric acid helps neurons stay selective
about the signals to which they respond with a state of relaxation [89]. Histamine as an
UAAs involves in local immune response and mediates allergic reactions [90]. On the
other hand, UAAs lead to protein or even organisms with enhanced function. Schultz et al
first introduced UAA into protein with providing an opportunity to examine the
evolutionary consequences as well as generate proteins with new or enhanced biological
functions [91]. The replacement of the natural L-amino acids with unnatural D-amino
acids can make the peptides resistant to protect themselves from degradation by
peptidases [92].

1.4.1 Unnatural Amino Acid Incorporation
The incorporation of UAAs into protein has attracted a lot of attention in chemical
biology and pharmeautical industry. This strategy not only aims to improve physiological
properties but also create artificial proteins for pharmeautical application. A variety of
methods have been developed to explore the incorporation of UAAs into proteins.
Herein, those methods for incorporation of UAAs have classified into three categories:
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translational incorporation of UAAs, semi-synthetic incorporation and bio-orthogonal
conjugation to UAAs and are described in the following.

1.4.1.1 Translational Incorporation of UAAs
The use of UAAs auxotrophic strains is the oldest method for UAAs
incorporation by use of auxotrophic Escherichia coli (E. Coli) strains. In this strategy,
incorporation of UAA into recombinant proteins exploits the unnatural substrate
tolerance of the native translational apparatus to accept amino acids analogues.
Therefore, two basic requirements should be met in the method. One is to prepare a set of
specific amino acid analogs, another is to create a targeted amino acids auxotrophic
strains. Tirrell et al successfully incorporated azido-homoalanine into protein (mDHFR)
with high translational efficiency. In this experiment, Methionine-tRNA synthetases was
used to accept several methionine analogs to incorporate into protein, only azidohomoalanine was recognized as a methionine surrogate and provided an opportunity to
chemoselective modification and labeling of proteins in native conditions [84]. Except
methionine, leucine [93], isoleucine [94], phenylalanine [95], tryptophan [96] and proline
[97] auxotrophic strains have been investigated to incorporate UAAs into proteins.
However, there are some basic issues to be addressed for ideal application. On one hand,
the tolerance to analogs for an aminoacyl tRNA synthetase (aaRS) could be different and
limited to further application. On the other hand, some amino analogs could be toxic to
microorganisms and cause function loss of protein since they are faked to the living
systems [98].
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1.4.1.2 Incorporation of UAAs by Nonsense Suppressor tRNAs
Due to drawbacks in use of auxotrophic strains, UAAs incorporation into proteins
by nonsense suppression has been used in attempts to replace a canonical amino acid with
an analog and has proven to be a valuable tool for structure-function studies [99, 100]. In
this strategy, the amber (UAG) nonsense codon was introduced to instead of the codon
for the amino acid of interest.

Since aaRS does not cross-react with any of the

endogenous tRNAs or any different aminoacyl tRNA synthetase, this replacement will
not recognize any of the common. As a result, desired amino acid will be recognized and
insertion because of suppression of the nonsense codon with an aminoacylated tRNA
[Figure 1.9]. Although it seems like a promising method to incorporate UAAs, its further
application has been limited due to strict criteria to meet: the suppressor tRNA must have
an efficient capacity to insert the UAAs and can not be recognized by any natural aaRS.
Furthermore, only one stop codon can be used for suppression, incorporation of different
UAAs into at one time becomes impossible [101].

Figure 1.9 Incorporating Unnatural Amino Acids into Proteins Using Nonsense Codon
Suppression. Reproduced from [102]
25

1.4.1.3 Incorporation of UAAs through Frameshift Suppression
To address those major disadvantages in the method of nonsense suppressor
tRNAs, Sisido and coworkers have modified this method and successfully developed a
remarkable approach for incorporation of UAAs, namely frameshift suppression, in
which four-base codons have been created to assign non-natural amino acids within the
framework of the existing three-base codon system.[103] Next, many more four-base
codons such as pairs (AGGU, CGGU, CCCU, CUCU, and GGGU) have been examined
and shown an high efficiency of 80% with respect to the wild-type protein [101]. Later,
codons have even extended to five-base codons such as CGGN1N2, where N1 and N2
could be one of four nucleotides and further expand the pool of codons for incorporation
of UAAs [104].This strategy has been performed by using a unique tRNA/aaRS pair not
only in E. coli but also in the eukaryotic cells such as the Xenopus oocytes [105].
Unfortunately, those efforts to perform frameshift suppression in Xenopus oocytes did
not succeed because of poor suppression efficiency. To update, Dougherty et al
appropriately designed two orthogonal frameshift suppressors (FS)-tRNAstwo tRNAs
with 4-base anticodons, in which both can deliver UAAs in response to the quadruplet
codons CGGG and GGGU. As a result, suppression efficiency was overcome by
successfully reducing incorporation of undesired UAAs into proteins in a Xenopus
oocyte [106]. This expanding size of codons makes it possible to incorporate several
different UAAs into proteins at one time.

1.4.1.4 Incorporation of UAAs by Creation of Unnatural Base Pairs
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Creation of unnatural base pairs is another strategy for the extension of the
genetic code. The most difficult challenge to expand size of codons is to synthesize novel
unnatural base pairs that are orthogonal to the natural types. The first new base pair has
been developed by Switzer et al. by creation of base pairs-isoC and isoG in 1989 [107].
The results confirmed that isoC and isoG base pair have been incorporated into DNA and
that the protein has successfully expressed with an UAA in the help of a synthetic tRNA.
Recently, a new non-natural named base-pyridine-2-one was developed by Hirao et al
[108] and successfully incorporated into a mRNA in a DNA template. Several unnatural
nucleotides base pairs with hydrophobicity has been created and used for incorporation of
triphosphate [109]. However, in the strategy chemical reaction was used for synthesis of
the mRNA and tRNA containing the non-natural bases; those unnatural base pairs must
be orthogonal and be recognized by the DNA polymerase and RNA polymerase. Taken
together, those factors above make it a long way to run before practical application.

1.4.2 Applications of Unnatural Amino Acid Incorporation
1.4.2.1 Identifying Structural and Functional Domains
Unnatural amino acid mutagenesis as a tool to investigate various structural and
functional protein domains has been studied extensively. For instance, cation-π
interaction, as an important noncovalent binding interaction relevant to structural biology
has attracted much attention [110, 111]. Particularly, cation-π interactions play a vital
role in biological recognition, especially in the binding of acetylcholine biology. Zhong et
al. explored this function by incorporating serial fluorine substitutions in Trp-149 of the
muscle type nAChR via unnatural amino acid mutagenesis [112]. In this research, a
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cation-π interaction between acetylcholine, a quarternary amine, with the ligand binding
domain of the nAChR was confirmed and pointed out electrostatic potential of the
tryptophan indole ring. Since lots of protein are supposed to have cation- cation-Π
interaction, incorporation of unnatural amino acid could be very useful tool to explore
this interactions. Also, the strategy of incorporation of UAAs has proven to be a powerful
tool for investigating protein dynamics. For example, the incorporation of fluorescent
side chains in an UAAs by using the nonsense suppression approach can monitor protein
conformational change [100, 113]. Furthermore, two kinds of fluorescent side chains can
be incorporated into one protein and provide an opportunity to explore cleavage of
protein [114]. Additionally, the role of individual hydrogen bonds in protein stability and
activity has been explored by incorporation of UAAs into proteins. A number of
unnatural amino acids and amino acid analogs were synthesized and replaced alanine-82
in T4 lysozyme to determine the effect of replacement on the stability of T4 lysozyme.
The replacements of alpha, alpha-disubstituted amino acids, N-alkyl amino acids
removed a hydrogen bond donor at those sites and reduced its stability and activity [115].

1.4.2.2 Inserting Functionalities into Proteins
Incorporation of UAAs into proteins provides a powerful tool to engineer proteins
with additional functionalities for special applications, especially for those functionalities
that cannot be introduced translationally into large, interesting proteins. For instance, pcarboxymethyl-L-phenylalanine can be incorporated into Tyr701 in human signal
transducer and activator of transcription-1 (STAT1) instead of phosphotyrosine to
improve resistant to hydrolysis by tyrosine phosphatases [116]. This directly introduce
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modifications in proteins provides a certification for protein engineering to expand
functions. Also, incorporation of UAAs into proteins has numerous applications in
protein tagging and protein conjugation. Several kinds of methionine analogs containing
azides into recombinant proteins for chemoselective modification have been incorporated
into murine dihydrofolate reductase (mDHFR) [102]. This incorporation of UAAs
containing azides provides very useful tool for a lots of application such as
bioconjugation, in vivo imaging, protein labeling or drug design and delivery by
Staudinger ligation and Click chemistry. For instance, site-specific PEGylation of human
thrombomodulin has been performed to increase half-time in the blood via Staudinger
ligation. [117]. An engineered LpIA acceptor peptide (LAP) with an alkyl azide have
been developed and further labeled in living mammalian cells [118]. This strategy
developed here provides an opportunity to biochemical and imaging studies of cell
surface proteins.
1.4.2.3 Studying Signal Transduction
Incorporation of UAAs into proteins is becoming a powerful tool for investigating
signal transduction pathways. A wide range of researches in vitro translation systems has
been performed to explore and understand signal transductions in E.coli or yeast express
systems by incorporation of UAAs. The protein phosphorylation is essential in regulating
signal transduction cascades associated with cancer and other biological processes.
Vázquez et al [119] studied phosphorylation dependent signaling by a series of
phosphorylated residues prepared via incorporation of sensitive fluorescent amino acid
DANA in the sequence RLYRpSLPA. The control of phosphorylation-dependent
signaling has been achieved by the development of phosphorylated residues and provided
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a useful tool to explore the role of protein phosphorylation in signal transduction
cascades.

1.4 Research Design and Rational
Thromboembolic

diseases

such

as

myocardial

infarction,

stroke,

and

thromboembolism are severe with significant mortality and morbidity in the United
States. Antithrombotic agents that prevent blood clotting can be used for both the
prevention and treatment of active vascular thrombosis. However, current antithrombotic
therapy is limited by the risk of series bleeding, hemorrhagic complication. A direct
correlation exists between the intensity of anticoagulation and severity of bleeding.
Recent advances in the molecular bases of haemostasis have highlighted new targets for
novel antithrombotic agent design. Specifically, endothelial thrombomodulin (TM) plays
a critical role in local haemostasis by binding thrombin and subsequently converting
protein C to its active form (APC. In addition, the binding of thrombin to TM drastically
alters the thrombin’s procoagulant activities to anticoagulant activities. Importantly, TM
expression, however, decreases in perturbed endothelial cells, predisposing to thrombotic
occlusion and particularly in response to a variety of inflammatory stimuli, direct vessel
wall injury, and oxidant stress. TM is a type I membrane protein. The lipid bilayer in
which it resides serves as an essential ‘cofactor’, locally concentrating and coordinating
the appropriate alignment of reacting cofactors and substrates for protein C activation.
Lipid membranes also play pivotal roles in activation of other anticoagulant enzymes. On
the other hand, liposomes have been extensively studied as cell surface model as well as
carrier for delivering certain vaccines, enzymes, drugs, or genes to the body. In this
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study, we hypothesized that combination of antithrombotic membrane protein TM into
lipid membrane mimetic assembly (liposome) through recombinant and bioorthogonal
conjugation techniques provides a rational strategy for generating novel and potential
antithrombotic agent (as shown in Figure 1.10). Namely, the liposomal TM conjugate
mimics the native endothelial antithrombotic mechanism of both TM and lipid
components and thus is more forceful than current antithrombotic agent.

Figure 1.10 Schematic Illustration of Proposed Membrane Mimetic Re-expression of
Membrane Protein onto Liposome.
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CHAPTER II
SURFACE FUNCTIONALIZATION OF LIPOSOME THROUGH STAUDINGER
LIGATION
(Partial results from Zhang, H. L., Ma, Y., Sun, X-L. Chem. Comm. 2009, 3032-3034)

2.1 Introduction
Liposome, a spherical closed self-assembled (phospho) lipids, has been
extensively studied as model of cell membrane and mostly as carrier for drug/gene
delivery applications [1, 2]. Liposome surface functionalization facilitates enormous
potential application of liposomes [3, 4]. Cell surface carbohydrates is attractive model
for liposome surface modification with oligosaccharides due to their protein-rejecting
ability, biodegradability, low toxicity, and especially, cell targeting ability through
specific binding interactions with receptors expressed at the targeted cells surface. For
example, monosialoganglioside (GM1) can enhance circulation lifetimes of liposomes
comparable to that observed for PEG [5]. Sialyl lewis X decorated liposome has been
demonstrated to target delivery of drugs to endothelial cells based on the site-specific
expression of E- and P-selectin on the blood vessel during inflammation [6]. On the other
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hand, carbohydrate-decorated liposomes have been used as multivalent platform of
carbohydrates to inhibit carbohydrate-mediated cell adhesion. For example, sialic aciddecorated liposome showed strong inhibitory activity against influenza hemagglunitin
and neuraminidase.
Conventional method to prepare surface functionalized liposome involves the
initial synthesis of the key lipid-ligand conjugate, followed by formulation of the
liposome with all lipid components. In this direct liposome formation method, some of
the valuable ligands inevitably are facing the enclosed aqueous compartment and thus
become unavailable for their intended interaction with their target molecules. Particularly,
it is unrealistic if the targeting ligand is only available in minimum amount. Furthermore,
lipid-ligand conjugates normally have limited solubility and stability in solvent, or are
incompatible with various stages of manufacture. Alternatively, chemical modification
methods, which in most cases involve the coupling of biomolecules to the surface of
preformed vesicles that carry functionalized (phospho)lipid anchors, have been developed
[8,9]. So far, variable success using amide [10] or thiol-maleimide coupling [11] as well
as by imine [12] or hydrazone linkage [13] have been achieved. However, in many cases
there is a lack of specificity resulting in the uncontrolled formation of the number of
covalent bonds between liposome and biomolecules of interest. Most recently, copper (I)catalyzed [3+2] cycloaddition, namely “Click” chemistry, which can occur efficiently in
aqueous media at room temperature and selectively between azide and alkyne [14] has
been investigated as novel generic chemical tool for the facile in situ surface modification
of liposomes [15]. However, the key limitation of the Click chemistry is the use of Cu (I)
catalyst, which results in residual copper in the targeted liposome preparations and could
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be a potential concern. Normally, it may be difficult to completely remove copper out
from the resultant liposome [15] and thus it will affect the liposome’s biological
application later on.
The Staudinger ligation, in which an azide and triphenylosphine selectively react
to form an amide has been used for chemical selective modification of recombinant
protein under native condition [16]. Recently, Staudinger ligation has been successfully
performed in living animals without physiological harm, suggesting the potential for
applications in cell surface functionalization [17]. Particularly, the reaction is known to
occur in high yield at room temperature in aqueous solvents and without any catalyst, and
is compatible with the unprotected functional groups of wide range of biomolecules.
Herein, we report an efficient and chemical selective liposome surface functionalization
with lactose as model carbohydrate through Staudinger ligation (Figure 2.1). The high
specificity and high yield as well as biocompatible reaction condition natures of the
Staudinger ligation approach make it an attractive alternative to all current protocols for
liposome surface functionalization.
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Figure 2.1 Schematic Illustration of Liposome Surface Glyco-Functionalization through
Staudinger Ligation.
2.2. Experimental
2.2.1 Materials and Methods
All solvents and reagents were purchased from commercial sources and were used
as received, unless otherwise noted. Deionized water with a resistivity of 18 Ω was used
as a solvent in all polymerization reactions.
Thin-layer chromatography (TLC) was performed on Whatman silica gel
aluminum backed plates of 250 nm thicknesses on which spots were visualized with UV
light or by charring the plate after dipping in 10 % H2SO4 in methanol. 1H NMR spectra
were recorded at room temperature with a Varian INOVA 300 MHz spectrometer. In all
cases, the sample concentration was 10 mg/mL, and the appropriate deuterated solvent
was used as an internal standard. Dynamic Light Scattering was recorded with 90Plus
particle size analyzer (BIC). Fluorescent spectrum was measured with FluoroMax-2 (ISA)
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Figure 2.2 Scheme of Synthesis of DPPE-Triphenylphosphine
2.2.2.1 Synthesis of 1-Methyl-2-Diphenylphosphinoterephthalate
1-Methyl-2-Diphenylphosphinoterephthalate (2) Dry MeOH (3ml), triethylamine
(TEA) (0.3 ml, 2 mmol), compound 1 (300 mg, 1.00 mmol), and palladium acetate (2.2
mg, 0.010 mmol) were added to a flame-dried flask. The mixture was degassed in vacuo.
While stirring under an atmosphere of Ar, and then diphenylphosphine (0.17 mL, 1.0
mmol) was added to the flask with a syringe. The resulting solution was heated at reflux
overnight, and then allowed to cool to room temperature and concentrated. The residue
was dissolved in 250 mL of a 1:1 mixture of CH2Cl2/H2O and the layers were separated.
The organic layer was washed with 1 M HCl (10 mL) and concentrated. The crude
product was dissolved in a minimum amount of methanol and an equal amount of H2O
was added. The solution was cooled to 4 °C for 2 hrs and the resulting solid was collected
by filtration. The pure product 3 was isolated as 245 mg (69 %) of a golden yellow solid,
mp 183–185°C. 1H NMR (400 MHz, CDCl3): 3.75 (s, 3H), 7.28–7.35 (m, 11H), 7.63–
7.67 (m, 1H), 8.04–8.07 (m, 1H).
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2.2.2.2

Synthesis

of

1-Succinimidyl

3-Diphenylphosphino-4-

Methoxycarbonylbenzoate
1-succinimidyl

3-diphenylphosphino-4-methoxycarbonylbenzoate

diphenylphosphino-4-methoxycarbonylbenzoic

acid

(216mg,

(4)

3,

3-

0.593mmol),

dicyclohexylcarbodiimide (DCC) (129mg, 0.623mmol), and N-hydroxysuccinimide
(NHS) (72 mg, 0.623 mmol) were dissolved in diethyl ether (20 mL) under Ar and stirred
overnight at room temperature. After the diethyl ether solvent was evaporated, the yellow
crystalline product was isolated by filtration. Recrystallization from 2-propanol (20 mL)
yielded 164 mg (60 %) of 3 as yellow crystals. 1H NMR (CDCl3, 400 MHz) (ppm): 8.15
(s, 2H), 7.67 (d, 1H, J ), 7.39-7.22(m, 10H), 3.75 (s, 3H), 2.82 (s, 4H, COCH2CH2CO);
13

C NMR (CDCl3, 75 MHz) δ169.4 (COCH2CH2CO), 166.7, 161.5, 143.0, 142.6, 140.1,

139.9, 137.0, 136.8, 136.6, 134.5, 134.2, 131.3, 130.2, 129.6, 129.2, 129.1, 128.1, 53.0,
26.0 (COCH2CH2CO); 31P NMR (CDCl3, 121 MHz), δ (ppm): -3.05

2.2.2.3 Synthesis of DPPE-Triphenylphosphine
DPPE (0.26 g, 0.376 mmol) was dissolved in 40 mL CH2Cl2, and 0.8 mL Et3N
was added. After stirring for 30 mins at room temperature, a solution of Succinimidyl 3Diphenylphosphino-4-methoxycarbonylbenzoate (4) (0.23 g, 0.500 mmol) in 50 mL
CH2Cl2 was added. The reaction mixture was stirred at room temperature for 24 hrs and
then concentrated. The crude product was purified by TLC using chloroform/methanol (4:
1) to afford 5 (0.283g, 73%).

1

H NMR (CDCl3, 400 MHz) δ (ppm):

121 MHz), δ(ppm)
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31

P NMR (CDCl3,

2.2.3 Preparation of Unilamellar Liposome for Surface Functionalization
DPPC

(30mg,

40.87

µmol),

cholesterol

(8mg,

20.4

µmol),

DPPE-

triphenylphosphine (3.5 mg, 3.2 µmol) (2: 1: 5 % molar ratio) were dissolved in 3.0 mL
chloroform. The lipid mixture was dried onto the wall of a 50 mL round-bottom flask and
the solvent was gently removed on an evaporator under reduced pressure to form a thin
lipid film on the flask wall and kept in a vacuum chamber overnight. Then, the lipid film
was swelled in the dark with 2.5 mL PBS buffer (pH 7.4) containing 85 mM
Carboxyfluorescein (CF) to form the multilamellar vesicle suspension. Followed to be
subjected 10 freeze-thaw cycles involving quenching in liquid N2 and then immersed in a
50 ℃ water-bath. The crude lipid suspension thus formed, followed by extruded through
polycarbonate membranes (pore size 2000 nm, 600 nm, 200 nm, 100 nm gradually) to
obtain the vesicles (LUVs) with approximately uniform diameter (110±5 nm). Separation
of the CF vesicles from non-entrapped CF was achieved by gel chromatography, which
involved passage through a 1.5×20 cm Column of Sephadex G-50), about 6ml liposome
were gained.

2.2.4 Lactose Coupling to Performed Liposome via Staudinger Ligation
To the liposome made in the part of preparation, added 4 mg azido-lactose in 0.2
mL PBS buffer (Argon bubble before use) into 2 mL liposome. The Staudinger ligation
was run at room temperature for 6h under an argon atmosphere, then the unreacted azidolactose was removed by gel filtration (1.5×20 cm Column of Sephadex G-50). The
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stability of liposome was monitored by FluoroMax-2 (ISA). The size of liposomes in the
Staudinger ligation was monitored over time by using 90Plus particle analysizer.

2.2.5 Determination of Lactose Density on the Surface of Liposome
The liposomes (5 mg/mL, total lipid concentration) separated from the column
was divided into two parts, one part was for reaction with lactose-azide, another was for
control.
Assay: 20 µL reaction solution and 1980 µL PBS were mixed, and then diluted
into 10 times.
Control: 20 µL original solution (5 mg/mL) and 1980 µL PBS were mixed and
then diluted into 10 times.
Standard curves of lactose assay: The method is that described by Dubois et al.
with some modifications. To 0.5 ml of lactose solution (20 μg/mL, 40 μg/mL, 60 μg/mL,
80 μg/mL, 100μg/mL, respectively), 0.5ml of 5% phenol solution was added and mixed.
Then 2.5 mL concentrated H2SO4 was added directly into the solution with 1-2 s. The
mixture was then vortexed, and allowed to stand for 30 mins at room temperature.
Readings were taken at 490 nm against a blank prepared by substituting distilled water
for the lactose solution (Figure 2.3).
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Figure 2.3 Standard Curves of Lactose Assay
Colorimetric analysis: To 0.5 mL of liposome with immobilized lactose, 0.5ml of
0.5 % phenol solution was added and mixed. Then 2.5 mL concentrated H2SO4 was
added directly into the solution with 1-2 s. The mixture was then vortexed, and allowed
to stand for 30 mins at room temperature. Readings were taken at 490 nm. The amount of
lactose from calibration curve was calculated.

2.2.6 Assay for Coupling Accessibility of Functionalized Liposome
To detect the lactose in the liposome, 0.5 mL PBS buffer (pH 7.4) including 0.5
mg lectin was added into 100 µL liposome conjugating the lactose. In the reaction, the
size of liposomes and stability of liposome in the reaction were monitored over time (0h,
1 h, 2 h, 3 h, 4 h), and a control was performed at the same conditions, too.

53

2.2.7 Evaluation of Stability of Functionalized Liposome by Dynamic Light
Scattering and Florescence Assay
The stability of liposome was also monitored by measurement of fluorescent
leakage using FluoroMax-2 (ISA). 20 µL reaction solution and 1980 µL PBS were mixed,
and then diluted into 10 times. The fluorescent intensity was measured by using
FluoroMax-2 (ISA). Control experiment was conducted in the absence of azide-lactose.
5, 6-carboxyfluorescein (CF) released from liposomes in PBS (pH 7.4) buffer at
room temperature was measured over time. The excitation and emission wavelengths of
5, 6-CF were 497 and 520 nm, respectively. The variation of the fluorescent intensity
with release time was calculated according to the equation below
Fraction of CF remaining in liposomes) = 1 - F/F0
where F is the fluorescent intensity measured at any time during the experiment and F0 is
the total fluorescent intensity measured after disrupting liposomes completely with 0.5%
Triton X-100 in PBS (pH 7.4) buffer.
Liposome size and distribution were analysized by dynamic/static light scattering
with 90Plus particle size analyzer (BIC).

2.3 Results and Discussion
2.3.1 Characterization of DPPE-Triphenylphosphine
As a proof-of-concept, we have explored the possibility to prepare glycosylated
liposomes by coupling unprotected lactosyl derivative carrying an ethyl spacer
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functionalized with an azide group to the surface of liposomes that incorporate synthetic
anchor lipids carrying a terminal triphenylosphine via Staudinger ligation. First, the
terminal triphenylosphine carrying anchor lipid 5 was synthesized by amidation of
commercially available DPPE with 3-diphenylphosphino-4-methoxycarbonylbenzoic
acid NHS active ester 4, which was prepared according to the procedure described by Ju
et al. [18] (Figure 2.4). However, it was found that an unwanted oxidation product,
triphenylosphine oxide 3 easily formed during crystallization purification of
triphenylosphine 2 by using aqueous methanol. The oxidized compound 3 was confirmed
by comparing with oxidation product of triphenylphosphine 2 with hydroperoxide in
methanol, which give a typical chemical shift at 34.2 ppm of phosphine oxide, while the
phosphine in 2 gives a chemical shift at -3.74 ppm in 31P NMR spectrum (Figure 2.3A).
Fortunately, the phosphine oxide 3 can be converted back to phosphine 2 by reduction
with trichlorosilane in toluene in high yield [19]. There is no oxidized product formed
during DPPE-triphenylosphine 5 synthesis and purification when organic solvents are
used. With this oxidation in mind, the stability of the intermediate triphenylosphine 2 and
the targeted lipid triphenylosphine conjugate 5 were monitored with 31P NMR. As results,
the oxidation of phophine 2 and 5 in organic solvent such as chloroform are very slow
(Figure 2.4B and 2.4C). Mass Spectrometry has been used to confirm its molecule weight
(1036) (Figure 2.4D)
A

B

C
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Figure 2.4 TLC traces and 31P NMR Study of Triphenylphosphine Derivatives

2.3.2 Integrity Assay of Liposome in and after Coupling Reaction
With the anchor lipid DPPE-triphenylosphine 5 in hand, next, small unilamellar
liposomes composed of saturated phospholipids (DPPC) and cholesterol (2: 1 molar
ratio) and 5 mol % of the anchor lipid 5 were prepared by extrusion through
polycarbonate membranes with pore size of 600 nm, 200 nm, and 100 nm sequentially at
65 ℃. This produced predominately small unilamellar vesicles with an average mean
diameter of 120 ± 5 nm as determined by dynamic light scattering (DLS). Next,
conjugation of azide-containing lactose ligands [20] to the preformed liposomes was
performed in PBS buffer (pH 7.4) at room temperature under an argon atmosphere for 6
hrs (Figure 2.1). DLS was used to verify the integrity of the vesicles during and after the
coupling reaction. As shown in Figure 2.5, there is no significant change in the size of the
vesicles during and after conjugation reaction. Therefore, the reaction conditions
described above do not alter the integrity of the liposomes.
A

B
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Figure 2.5 Dynamic light scattering monitoring of liposome, A: before conjugation, B:
after conjugation
Next, to test whether the experimental conditions used for the conjugation
reaction could provoke some leakage of the liposomes, we have exposed our standard
conditions to the same type of liposomes having encapsulated self-quenching
concentrations of 5, 6-carboxyfluorescein [21]. Based on the fluorescence quenching
determinations (Figure 2.6), we could demonstrate that no apparent leakage was triggered
by the conjugation reaction compared to the liposomes incubated in the absence of the
coupling reagents. Therefore, the conjugation conditions established here are harmless for
liposome surface functionalization.
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Figure 2.6 Kinetics of carboxyfluorescein release from liposome in the presence of
lactose-azide (A) and in the absence of lactose-azide (control experiment) (B). Insert
shows the changes of fluorescence intensity of liposomes suspension of reaction and
control during conjugation and final decomposition with surfactant.

2.3.3 Quantification of Lactose on the Surface of Liposome
Furthermore, the grafted carbohydrate on the surface of liposome was quantified
by the phenol-sulfuric acid method [22]. Briefly, phenol solution was added to a solution
of liposome with conjugated lactose, and mixed. Then concentrated H2SO4 was added
directly into the solution. The mixture was then vortexed, and allowed to stand for 30
mins at room temperature. The optical density was then recorded at 490 nm. Considering
that about 40 % of the triphenylosphine anchor is oriented toward the interior of the
vesicles, 80 % of the out-oriented triphenylosphine have been modified in this Staudinger
ligation modification.
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2.3.4 Assay for Coupling Accessibility of Functionalized Liposome
To determine whether the grafted lactose residues are easily accessible at the
surface of liposomes, lectin binding assay was conducted by incubating lactosylated
liposome in the presence of galactose binding lectin (Arachis hypogae, 120 kDa, Sigma)
in PBS (pH 7.4). After 30 mins, apparent visible aggregation formed and was monitored
in DLS experiment (Figure 2.7A). In contrast, neither aggregation nor size change was
observed with control liposomes without lactose. Furthermore, the presence of free
lactose (5.0 mM) prevented aggregates formation (not shown), confirming that the
agglutination was due to a specific recognition of the lactose residues on the surface of
the liposomes by lectin in multivalent interactions (Figure 2.7B).
A

B
Liposome-lactose + lectin
RT/6h

100

Intensity

80
60
40
20
0

500

1,000

1,500

2,000

2,500

Diameter (nm)
Multimodal particle size distribution

3,000

Figure 2.7 Agglutination glycosylated liposome with lectin via multivalent interaction
(A) and monitored with DLS (B)

2.3.5 Evaluation of Stability of Functionalized Liposome
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The stability of liposomes over time is an important concern in drug/gene delivery
application. It is known that monosialoganglioside (GM1) could enhance circulation
lifetimes of liposomes comparable to that observed for PEG. In this study, the stability of
the lactosylated liposome was evaluated by comparing with liposome without lactose at
room temperature as monitored with DLS. As shown in Figure 5, both liposomes showed
good stability during the eight days period. However, the liposome without lactose began
to collapse and aggregate since 9th day (Figure 2.8A), while there were no apparent size
change for the lactosylated liposome (Figure 2.8B). This result demonstrated that the
presence of lactose on the liposome surface provides a stereic barrier that prevents
liposome aggregation.
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Figure 2.8 Stability of liposome without lactose (A) and liposome with lactose (B)
monitored with DLS
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2.4 Conclusion
In conclusion, we have developed an efficient and chemoselective conjugation
method for liposomes surface glyco-functionalization based on Satudinger ligation. The
reaction could be performed under mild conditions in aqueous buffers without catalyst
and in high yields under reasonable reaction times. The reaction conditions developed in
the present work did not alter the integrity of the bilayers, in terms of liposome sizes and
leakiness, and provided perfectly functional vesicles. This versatile approach, which is
particularly suitable for the ligation of water soluble molecules and which can
accommodate many chemical functions, is anticipated to be useful in the coupling of
many other ligands onto liposome.
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CHAPTER III
INCORPORATION OF UNNATURAL HOMOANALINE INTO
RECOMBANANT THROMBOMODULIN FOR SITE SPEIFIC CONJUGATION
(Protocol modified from Cazalis, C. S., Haller, C. A., Sease-Cargo, L., Chaikof, E. L.
Bioconjug. Chem. 2004, 15, 1005–1009)

3.1 Introduction
Thrombomodulin (TM) is an endothelial anticoagulant protein that contributes to
local hemostatic balance by modulating the activity of thrombin from a procoagulant to
an anticoagulant protease [1–3]. Through binding with thrombin to form complex on the
endothelial surface, TM removed thrombin’s procoagulant properties by stopping
cleavage of fibrinogen or activation of platelets. At the same time, the TM-thrombin
complex involves in protein C activation pathway in which protein C is bound to TMthrombin complex to immediately enhance activation over 1,000 fold. Subsequently, the
activated form of protein C (APC), an anticoagulant protease, selectively inactivates
coagulation factors Va and VIIIa, providing an essential feedback mechanism in
preventing excessive coagulation. TM has been considered as one of key factors
contributing to thrombotic regulation [4]. It also has been reported that reduction in TM
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activity, induced by a targeted point mutation or injection of anti-TM antibodies in mice,
makes the animals more susceptible to thrombogenic challenges [5, 6]. Administration of
exogenous recombinant TM to these animals has shown antithrombotic effects. In the
past decades, various recombinant TM proteins consisting of extracellular portions have
shown potential anticoagulant activity [7–12]. One such example is recombinant human
soluble TM α (rhsTMα or ART-123), which was used in Japan to treat patients with
disseminated intravascular coagulation (DIC) [12, 13].
The structure of TM and its structural domains necessary for activation of protein
C have been resolved. The fifth and sixth EGF domains of TM represent the binding site
of thrombin, while the fourth EGF domain is responsible for protein C activation, all
which are related to TM’s anticoagulant activity [2, 3]. However, TM’s third EGF-like
domain is of equal importance in the thrombotic cascade accelerating the proteolytic
activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin [14]
Activated TAFI (TAFIa) cleaves C-terminal lysine and arginine residues from partially
degraded fibrin. The removal of these positively charged residues suppresses the ability
of fibrin to catalyze plasminogen activation and thereby delays clot lysis [15]. Therefore,
recombinant TM containing all extra cellular portions of TM simultaneously functions as
a procoagulant and anticoagulant which would be reasonably ineffective as an
anticoagulant therapeutic. Consequently, recombinant TM containing the EGF-like
domains 456 (rTM456) is the only engineered TM recombinant considered to be a
potential candidate as a pure anticoagulant [16–19]. The smaller protein fragment, from a
bioengineering standpoint, provides an opportunity through manipulation and
modification to optimize and generate a feasible biotherapeutic.
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Incorporation of unnatural amino acids to proteins has become a very popular tool
to expand protein’s functions and shown its promising potential in chemical biology and
pharmaceutical industry. To date, lots of methods have been explored to study
incorporation of unnatural amino acids for widely applications such as protein-protein
interaction, biophysical probes and creation of functionality [20]. Since Levine et al. [21]
firstly introduced auxotrophic bacterial strains for incorporation of unnatural amino acids,
this strategy has been studied extensively and become commercially available to
numerous biology studies. In this strategy, the native translational apparatus recognized
analogs of natural amino acids to provide an opportunity to accept unnatural amino acid
analogues for incorporation to protein. Kiick et al. [22] successfully incorporated azidohomoalanine into protein (mDHFR) with high translational efficiency under help of
Methionine-tRNA synthetases for acceptance of methionine analogs. To only incorporate
azido-homoalanine into protein, natural methionine was removed from media to exclude
side incorporation of methionine. This study developed here provided an opportunity to
chemoselective modification and labeling of proteins in native conditions. In this study,
we propose that the insertion of homoalanine into protein TM containing the EGF-like
domains 456 (rTM456) by auxotrophic E.Coli strain to attain an optimal platform for
exploring site specification modification of recombinant TM (Figure 3.1).
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Figure 3.1 Schematic Structure of the Site-Specific Azide Functionalized Consecutive
EGF-like Domains 4-6 of Human TM with His-Tag and S-Tag

3.2 Experimental
3.2.1 Materials and Methods
All solvents and reagents were from commercial sources and were used as
received, unless otherwise noted. Deionized water was used as a solvent in all
experiments. Human thrombomodulin cDNA clone was from ATCC (Manassas, VA),
pET Dsb Fusion System 39b, competent cells, and kanamycin sulfate were from EMD
Chemicals (Philadelphia, PA). Phusion® High-Fidelity PCR Kit, BamHI-HF, KpnI-HF,
T4 DNA ligase and alkaline phosphatase were from New England Biolabs (Ipswich,
MA). All plasmid purification kits were from QIAGEN Inc. (Chatsworth, CA). E. coli
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strain B834 (DE3), plasmid pET-39b(+), and Site-Specific Enterokinase Cleavage and
Capture kits were from Novagen (Madison, WI). The mouse monoclonal antibody
specific to human TM was from COVANCE Corp. (Richmond, CA).

Synthetic

oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville,
IA). Purified recombinant human PC and human thrombin were from Haematologic
Technologies Inc. (Essex Junction, VT). Human anti-thrombin, recombinant human TM
and chromogenic substrate Spectrozyme PCa were from American Diagnostica Inc.
(Stamford, CT). L-azidohomoalanine was from AnaSpec Inc. (Fremont, CA). Imidazole,
sodium azide, other chemicals were from Sigma-Aldrich (USA). Fluorescence imaging
of SDS-PAGE gels was performed using a Typhoon 9410 Variable Mode Imager
(Amersham Biosciences, USA). Dialysis was performed using cellulose membranes with
a molecular weight cutoff of 3.5 kDa with water as solvent. OD value was recorded on a
Varian Bio50 UV-vis spectrometer.

3.2.2 Construction of Mutant of TM EGF-like (4-6) Domain
Plasmid Constructs. Recombinant thrombomodulin EGF456 was prepared by
expressing plasmid TM456-N3 in E. coli methionine auxotroph B834 (DE3). To encode
thrombomodulin EGF 4-6 domains, forward primer: 5' CGC GGA TCC CGA CCC GTG
CTT CAG A 3' and reverse primer: 5' GTT GCA AAA CAG CTG GCA CCT GTG 3'
were used to create a mutant with C terminal methionine based on human
thrombomodulin cDNA, in which unnatural amino acid could be incorporated into
recombinant proteins to provide an azide group for chemoselective modification. To
remove extra methionine in other sites of the mutant and to improve resistance to
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oxidative inactivation and enzymatic activity, a point mutation was created to switch
methionine to leucine at position 388 by using forward primer 5’ CAC AGG TGC CAG
CTG TTT TGC AAC 3' and reverse primer 5' CGC GGA TCC GAT TAC ATA CC C
CCC AC 3'. PCR fragments containing the mutant sequences were ligated into pET 39
b(+) to make the expression plasmid TM456GGM. The sequence of each mutant plasmid
was confirmed by DNA sequencing.

3.2.3 Incorporation of Azides into TM456 in E.coli and Protein Extraction
Media and materials for E. coli culture were prepared as following:
Table I. Media A for Single Colony Culture (10ml)
Materials

Volume

Sterilization

M9 medium (1 x)

10 mL

autoclave

MgSO4 (1 M)

10 µL

0.22 μm Filter

CaCl2 (1 M)

1 µL

0.22 μm Filter

20% D (+) Glucose

200 µL

0.22 μm Filter

Thiamine Hydrocloride (1 mg/mL)

10 µL

0.22 μm Filter

19AA W/O Methionine

400 µL

0.22 μm Filter

L-Methionine solution (20 mg/mL)

20 µL

0.22 μm Filter

Kanamycin (35 mg/mL)

10 µL

0.22 μm Filter
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Table II. Media B for Scale Up Culture (1 L)
Materials

Volume

Sterilization

M9 medium (5 x) (autoclave)

200 mL

autoclave

dH2O

720 mL

autoclave

MgSO4 (1 M)

1 mL

0.22 μm Filter

CaCl2 (1 M)

100 µL

0.22 μm Filter

20% D (+) Glucose

20 mL

0.22 μm Filter

Thiamine Hydrocloride (1 mg/mL)

1 mL

0.22 μm Filter

19AA W/O Methionine

40 mL

0.22 μm Filter

L-Methionine solution (20 mg/mL)

1 mL

0.22 μm Filter

Kanamycin (35 mg/mL)

1 mL

0.22 μm Filter

The recombinant TM456-N3 was expressed in E. coli as the following procedure:
1.

Transform the constructed TM456GGM to the appropriate E. coli strain and plate
out on minimal medium plates. Incubate the plates overnight at 37°C.

2.

Pick one colony and use it to inoculate 10 mL Media A. Incubate the culture on
orbital incubator (180 rpm) overnight at 37°C.

3.

Add the overnight culture to 1 L medium B plus 2mL L-Methionine (20 mg/mL)
and incubate the culture at the appropriate temperature for induction until the
absorbance at 600 nm is 0.8.

4.

Centrifuge the cell suspension for 5 mins at 4,500 rpm at 4°C.

5.

Washing cell pallets with 1 × M9 solution (autoclave)
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6.

Centrifuge for 5 mins at 4,500 rpm at 4 °C. Repeat 2 more times

7.

Resuspend the pellet in 1 L Medium B (without methionine) and incubate for 1 hr
at 37 °C to starve the cells

8.

Add 2 mL Azidohomoalanine (20 mg/mL) and incubate for a further 30 mins.

9.

Induce expression of the target protein by adding 1.2 mL IPTG (500 mM) to the
medium and incubate the culture at 25 °C overnight.

10. Centrifuge the cell suspension for 10 mins at 8000 x g at 4 °C.
11. Store the cell pellet at -20 °C or -80 °C when not immediately used.
In the expression of rTM456-N3, a culture lacking methionine served as the
negative control. After cells were harvested by centrifugation for 30 mins at 4 °C, lysis
buffer (20 mM Tris-HCl, pH 8.0, and 300 mM NaCl) with the protease inhibitor PMSF
(10 µg/mL) was added to a total volume of 50 mL. The cells were then sonicated every 2
min with a probe sonicator (Sonifier 450, Branson Ultrasonics, CT) on ice. Cell
disruption was evidenced by partial clearing of the suspension. Then the broken cells
were centrifuged 15000 x g for 30 mins and the supernatant was collected and directly
applied to an immobilized metal affinity column (HisTrap FF) equilibrated with washing
buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, and 20 mM imidazole). The column
was washed with 10 column volumes of washing buffer, after which the column was
flushed with 3 column volumes of cleavage buffer (20 mM Tris-HCl, pH 8.0, 300 mM
NaCl, and 250 mM imidazole) to afford His-rTM456-N3. Finally, enterokinase was used
for site-specific cleavage to remove the fusion tag and generate the target protein rTM456N3.
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A similar procedure was used for preparing positive control protein His-rTM and
rTM456 without incorporation of azide group. Briefly, the expression plasmid TM456GGM
was transformed into E. coli BL21 (DE3) cells. Bacteria were grown in LB media under
the same conditions. rTM purification and fusion tag removal were performed under the
same conditions.

3.2.4 Western Blot for Identification of rTM456
After purification rTM456 from HisTrap FF and followed by cleavage by
enterokinase, SDS-PAGE gel electrophoresis was used to separate recombinant TM456
with his tag and recombinant TM without his tag. 12 % Tris–glycine gels was made in
the lab and used throughout. Electrophoresis was performed on XCell SureLock™ MiniCell Electrophoresis System (Invitrogen). The running buffer is 1X tris-glycine-SDS
buffer. 20 µL solution was loaded into wells for each sample. Electrophoresis was run at
120 V for 2 hrs. After the gel has run, samples were transfer to nitrocellulose membrane
at 90 V for 45 mins. The mouse monoclonal antibody specific to human TM was for
binding of rTM. ECL kit (GE Healthcare) was use for detection of proteins.

3.2.5 Mass Spectrometry Analysis of Recombinant TM456
After electrophoresis, the gels immediately was rinsed in dH2O, and then
immersed into Zinc-imidazole staining buffer (Bio-rad). After staining, the gel was rinsed
completely in dH2O. Then protein bands was cut from gel and destained according to
standard protocols as instruction. Next, 2 or 3 pieces of gels were crushed and immersed
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into 1mL extraction buffer (Formic acid/ water/2-propanol (1:3:2 v/v/v) (FWI) for 2hrs.
Then samples were centrifuged at 15, 000 rpm for 20 mins. The supernatant was
collected for MALDI-TOF analysis.
The extraction solution was lyophilized and a MALDI matrix solution (FWI
saturated with 4-hydroxy-a-cyano-cinnamic acid (4HCCA)) was added to redissolve and
prepare the protein for MS analysis using the dried-drop method of matrix crystallization
[23]. The MALDI MS experiments were carried out on a Bruker Ultraflex III tandem
time-of-flight (TOF/TOF) mass spectrometer (Bruker Daltonics, Billerica, MA),
equipped with a Nd:YAG laser emitting at a wavelength of 355 nm. All spectra were
measured in positive reflector mode. The instrument was calibrated externally with a
poly(methyl methacrylate) standard prior to each measurement. Five different matrices
were used: dithranol (DIT), 2,5-dihydroxybenzoic acid (DHB), and trans-2-[3-(4-tertbutylphenyl)-2-methyl-2-propenylidene]

malononitrile

(DCTB)

dissolved

in

tetrahydrofuran (THF) at 20, 10, and 20 mg/mL, respectively, as well as 3-hydropicolinic
acid

(HPA)

and

R-cyano-4-hydroxycinnamic

acid

(CHCA)

dissolved

in

acetonitrile(ACN)/water (v/v, 50/50) at 5 mg/mL. Samples were prepared by sandwich
method involving depositing 0.5 μL of matrix solution on the wells of a 384-well groundsteel plate, allowing the spots to dry, then depositing 0.5 μL of each sample on top of a
dry matrix spot, and adding another 0.5 μL of matrix solution on top of the dry sample
(sandwich method). MALDI experiments were performed using Bruker’s LIFT mode.
Data analysis was conducted with the flexAnalysis software.

3.2.6 Availability of Azide Moiety in the Recombinant TM456
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Samples of His-rTM456-N3 and rTM456-N3 were incubated with cyclooctyne
functionalized Fluorescent dye Alexa Fluor® 647 DIBO (10 equiv, Invitrogen) in a
phosphate buffer (pH 7.0) for 1 hr at room temperature. Then samples were dialyzed in
Tris-HCl (20 mM, pH 7.4) for overnight. Next, samples were load into 12% tris-glycine
gel for separation and carried out at 120 V for 1.5 hrs. Coomissee blue was used to stain
gel. rTM456 without azide was used as a negative control and subjected to the same
reaction conditions. Finally, an imaging system (Typhoon 9410 Variable Mode Imager,
Amersham Biosciences, USA) was used to analysize the fluorescent labeled proteins on
the gel.

3.2.7 Cofactor Activity Assay of rTM
The activity of rTM456 was defined as moles of produced APC per min by given
amounts of rTM456 protein in the presence of thrombin. All activations of protein C by
rTM conjugates were performed for 60 min in 20 mM Tris-HCl buffer, pH 7.4, 100 mM
NaCl, 0.1% BSA, and 5 mM Ca2+ at 37°C.
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Thrombin (10 nM): 10 µL
TM or TM mutant (1 nM): 10 µL
Protein C (5 µM):10 µL
Buffer (Tris-HCl, BSA 0.1 %, Ca 2+ 2.5 mM, pH 7.4): 70 µL

37 ℃, 60 mins

Antithrombin III (90 µg/µL): 3 µL
Heparin (2500 IU/mL): 2 µL

37 ℃, 5 mins

PCa (4.4 mM): 5 µL (0.2 mM)
final)

37 ℃, 10 mins
Acetic Acid (20 %): 200 µL
Buffer (Tris-imadole, pH 7.4): 700 µL

Assay by APC Calibration Curve
Figure 3.2 Flow Chart for Cofactor Activity Assay of TM
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Typically, 20 nM thrombin and different rTM concentrations (1, 1.5, and 2 nM)
were incubated in the assay buffer. After 60 mins, 3 µL antithrombin III (90 µg/µL) and 2
µL heparin (2500 IU/mL) were added into the solution to stop the reaction. The inhibition
of protein C activation was completed within 5 mins at room temperature. The produced
APC was measured through hydrolysis of a chromogenic substrate (Spectrozyme PCa) by
comparing a standard curve (Figure 3.3), in which the concentration of APC to the rate of
p-nitroanilide (pNA) formation was measured. The hydrolysis of Spectrozyme PCa was
performed for 10 mins in the assay buffer at 37 °C, in which pNA was produced and the
concentration measured by monitoring at λ = 405 nm with a spectrophotometer.

Figure 3.3 Standard Curve of Activated Protein C Assay

3.3 Results and Discussion
3.3.1 Construction of TM Mutant with Leucine Mutagenesis
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A truncated TM fragment containing EGF4-6 with the insertion of a C-terminal
non-natural methionine analogue was chosen as our target antithrombotic protein for sitespecific conjugation [19]. Specifically, a truncated recombinant TM mutant containing
amino acid sequences 349-492 with a Met-388-Leu substitution and a C-terminal linker
GlyGlyMet-N3 was constructed using site-directed mutagenesis (Figure 3.1).
In the construction of plasmid, two mutant fragments were created for
mutagenesis from methonine to leucine by point mutation. This mugagenesis here could
improve resistance to oxidation by using leucine instead of methionine at 388 [24]. The
first fragment from Asp to inserted leucine has 118 base pairs; while the second
fragments from leucine to methonine in the terminal has 323 base pairs. The sizes of
those fragments have been confirmed by DNA analysis on agarose electrophoresis
(Figure 3.4).

Figure 3.4 DNA Gel Analysis for Fragment: marker (lane 1), the fragment from Asp to
inserted leucine (lane 2), from leucine to methonine (lane 3) and whole mutant (lane 4)
After construction of TM456GGM, it was transformed into competent cells. Then,
quantities of DNA encoding EGF-like 4-6 domain with a mutation of leucine at 388 have
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been expressed in E. coli and harvested for DNA sequencing. The sequence of each
mutated gene determined by DNA sequencing was following and was matched with its
DNA sequence (marked by red and underline) as designed.
MKKIWLALAGLVLAFSASAAQYEDGKQYTTLEKPVAGAPQVLEFFSFFCPHCYQ
FEEVLHISDNVKKKLPEGVKMTKYHVNFMGGDLGKDLTQAWAVAMALGVEDK
VTVPLFEGVQKTQTIRSASDIRDVFINAGIKGEEYDAAWNSFVVKSLVAQQEKAA
ADVQLRGVPAMFVNGKYQLNPQGMDTSNMDVFVQQYADTVKYLSEKKGSTSG
SGHHHHHHSAGLVPRGSTAIGMKETAAAKFERQHMDSPDLGTDDDDKSPGFSST
MAIDPDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHEPHRCQLFCNQTACPAD
CDPNTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSAL
ARHIGTDCDSGKVDGGDSGSGEPPPSPTPGSTLTPPAVGGM

3.3.2 Mass Spectrometry Characterization of rTM456
In this study, recombinant TM456 with His-tag and S-tag at the N-terminal and an
azidohomolananine at the C-terminal was expressed in E. coli. Protein expression was
confirmed by MALDI-TOF mass spectrometry (Figure 3.5). Other than Commisse blue,
zinc –imidazole was used for protein staining. This staining method for protein detection
is reversible and suitable for intake protein identification. Compared to other stains, it
yields good efficiency and intact protein without need of digestion. The measured values
fit for calculated molecular mass of His-rTM-N3 (43192 D) and rTM-N3 (16645 D).
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Figure 3.5 Mass Spectrometry for Characterization of His-rTM-N3 and rTM-N3

3.3.3 Availability of Azide Moiety in the Recombinant TM
The recombinants were further analyzed by SDS-PAGE and visualized by
Coomassie blue staining (Figure 3.6A). The target recombinant TM fused to the leader
sequence was clearly detected in the positive control cultures supplemented with
azidohomoalanine, whereas it was not observed in the negative control culture. The
recombinant TM with His-S tags was purified from the cell pellet by using metal-affinity
chromatography with stepwise imidazole-gradient elution under native conditions. The
rTM456-N3 was characterized by identification of a band at ~20 kDa on SDS-PAGE gels
(Figure 3.6A), which was consistent with prior reports [19]. To investigate whether the
azide moiety in the protein was reactive under copper-free click chemistry condition,
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both His-rTM456-N3 and rTM456-N3 were incubated with cyclooctyne functionalized
Fluorescent dye Alexa Fluor® 647 DIBO (10 equiv, Envitrogen) in a phosphate buffer
(pH 7.0) overnight at room temperature. rTM456 without azide was used as a negative
control and subjected to the same reaction conditions. Protein samples were dialyzed
against the buffer to remove unreacted fluorescent dye and then analyzed by SDS-PAGE.
The gel was stained with Coomassie blue (Figure 3.6A) and the fluorescent image from
the gel were detected using an imaging system (Typhoon 9410 Variable Mode Imager,
Amersham Biosciences, USA) (Figure 3.6B). As a result, the band for His-rTM456-N3 and
rTM456-N3 were fluorescent, whereas no fluorescent image was detected from rTM456
without an azide group. These results indicated that the azide moiety in the protein was
reactive toward the cyclooctyne and could be conjugated to cyclooctyne-containing
molecules under copper free click chemistry condition.

Figure 3.6 SDS-PAGE (12%) characterization of recombinant TM derivatives:
Coomassie blue staining, B. Fluorecence scanning

3.3.4 Cofactor Activity Assay of rTM
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A.

In this study, protein C activation activities of the rTM were evaluated. The
activity of rTM456 was defined as moles of produced activated protein C per min by given
amounts of rTM456 and rTM456 conjugates in the presence of thrombin. As shown in table
III, recombinant His-TM456-N3 and TM456-N3 have shown similar protein c activity as
commercial full TM. Taken together, rTM456 has been successfully expressed in present
study without apparent loss of protein C activity.
Table III. Protein C Activation Activity of rTM

Km(μM)
kcat(min-1)

His-rTM-N3

rTM-N3

0.60±0.15

0.80±0.2

0.90±0.2

(0.90±0.2)

(1.0±0.5)

0.28±0.05

0.24±0.04

(0.22±0.05)

(0.16±0.05)

0.40±0.15

0.29±0.11

(0.26±0.1)

(0.16±0.05)

0.20±0.03
0.37±0.14

kcat/Km
-1

Full TM*

-1

(min .μM )

*commercial full TM of human, the data in parentheses from [19]

3.4 Conclusion
In this study, unnatural amino acid-azidohomoalanine was successfully
incorporated into TM at the C terminal by directly acceptance of methionine analogs
under help of Methionine-tRNA synthetases. This incorporation of azidohomoalanine
provides an azide moiety for site specific conjugation through Staudinger ligation and
Click chemistry, and makes an alternative to explore protein interaction and the effect of
cell membrane to integral protein by membrane mimics.
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CHAPTER IV
SYNTHESIS AND CHARACTERIZATION OF ANTITHROMBOTIC
LIPOSOMAL THROMBOMODULIN VIA STAUDINGER
LIGATION

4.1 Introduction
Membrane proteins are becoming most investigated drug targets and have been
studied extensively in biology sciences and pharmaceutical industry since they involve
most of physiological process such as signal transduction, control of metabolic process
and inspiration of immune systems. The tools today for studying and characterizing
proteins have paved the way for membrane protein investigation and provide an
opportunity to understand this kind of proteins and create novel drug targets. However,
there are still some unexpected challenges to meet when membrane proteins are
considered as novel drug targets, for example, extremely difficulty to purify, easily
activation by removing from cell membrane and so on [1]. Liposome incorporated
proteins provide protection from inactivation of membrane protein by mimicking real cell
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membrane and become a very usefully tool to study physiological functions of membrane
proteins [2, 3].
To date, liposome incorporated proteins are usually prepared by post-insertion
method. In this strategy, target proteins are extracted from cell membrane and form
micelles in buffer. Then micelles containing membrane proteins are incubated with
performed liposome to form liposome incorporated membrane proteins by fusion
interaction between hydrophobic tail of proteins and liposome. Detergents or organic
solvents are required for their solubilization and purification [4]. However, detergents are
difficult to remove completely, and can lead to toxicity in vivo. Furthermore,
conformational change of proteins could happen and decrease activity or even loss of
function due to random orientation [5]. Chemical modification methods, namely postfunctionalization methods, provide an alternative to prepare liposome incorporated
proteins, in which in most cases involve the coupling of biomolecules to the surface of
preformed vesicles that carry functionalized lipid anchors [6]. Compared to post-insertion
method, this strategy was designed to orient modification and reduced possibility of
random confirmation. On the other hand, it provides an opportunity to incorporate
proteins into liposome without help of hydrophobic tailor of membrane proteins, in turn,
which makes it easier to prepare target proteins. So far, variable coupling methods have
been studied for post-surface functionalization by using amide [7] or thiol-maleimide
coupling [8], imine [9], hydrazone linkage [10] as well as bioorthogonal conjugation
methods including native chemical ligation (NCL) [11], Staudinger ligation [12] or Click
chemistry [13]. Among of current coupling methods, the Staudinger ligation is a widely
used method for bioconjugation in lots of applications such as DNA labeling [14],
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peptide-peptide conjugation [15], cell surface engineering [16] as well as drug delivery
systems [12]. This reaction occurs in native condition with high yield and without any
catalyst and is compatible with the unprotected functional groups of wide range of
biomolecules.
Incorporation of non-natural amino acid into proteins provides a powerful tool to
engineer proteins with additional functionalities for special applications, especially for
those functionalities that cannot be introduced translationally into large proteins, as well
as applications in protein tagging and protein conjugation. For instance, several kinds of
methionine analogs containing azides into recombinant proteins for chemoselective
modification have been incorporated into murine dihydrofolate reductase (mDHFR) [17].
This incorporation of UAAs containing azides provides very useful tool for a lots of
application such as bioconjugation, vivo imaging, protein labeling or drug design and
delivery by Staudinger ligation and Click chemistry. For example, site-specific
PEGylation of human thrombomodulin has been performed to increase half-time in the
blood via Staudinger ligation. [18]. An engineered LplA acceptor peptide (LAP) with an
alkyl azide have been developed and further labeled in living mammalian cells which
providing an opportunity to biochemical and imaging studies of cell surface proteins [19].
Particularly, TM is a type I membrane protein. The lipid bilayer in which it
resides serves as an essential ‘cofactor’, locally concentrating and coordinating the
appropriate alignment of reacting cofactors and substrates for protein C activation.
Liposomes have been extensively studied as cell membrane model as well as carrier for
delivering certain vaccines, enzymes, drugs, or genes to their active sites. Herein, we
have

explored

regio-

and

chemoselective
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functionalization

of

recombinant

thrombomodulin (TM) to liposome surface via Staudinger ligation in order to mimic the
native endothelial antithrombotic mechanism of both TM and lipid components and thus
will provide a more forceful than current antithrombotic agent (Figure 4. 1).

Figure 4.1 Schematic Illustration of Proposed Membrane Mimetic Re-expression of
Membrane Protein TM onto Liposome

4.2 Experimental
4.2.1 Materials and Methods
All solvents and reagents were from commercial sources and were used as
received, unless otherwise noted. Deionized water was used as a solvent in all
experiments. The mouse monoclonal antibody specific to human TM was from
COVANCE Corp. (Richmond, CA). Purified recombinant human PC and human
thrombin were from Haematologic Technologies Inc. (Essex Junction, VT). Human antithrombin, recombinant human TM and chromogenic substrate Spectrozyme PCa were
from American Diagnostica Inc. (Stamford, CT). L-azidohomoalanine was from AnaSpec
Inc. (Fremont, CA). 1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC), 1,2-disteroyl-sn88

glycero-3-phosphoethanol-amine-N-[amino(polyethylene glycol)3400](ammonium salt)
(DSPE-PEG3400-NH2)

were

from

Laysan

Bio

Inc.

(Arab,

AL).

Cholesterol,

dicyclohexylcarbodiimide (DCC), diphenylphosphino-4-methoxycarbonylbenzoic acid,
hexaethylene glycol, toluene sµlfonyl chloride, imidazole, sodium azide, Nhydroxsuccinimidobiotin, N,N-dimethylformamide and other chemicals

were from

Sigma-Aldrich (USA).
Mass spectrometry experiments were performed using QSTAR Elite mass
spectrometer (Applied Biosystems, Foster City, CA). Data was conducted with Analyst®
QS 2.0 software. Thin-layer chromatography (TLC) was performed on Whatman silica
gel aluminum backed plates of 250 μm thicknesses on which spots were visualized with
UV light or by charring the plate after dipping in 10% H2SO4 in methanol. Fluorescence
imaging of glass slide was performed using a Typhoon 9410 Variable Mode Imager
(Amersham Biosciences, USA). Dialysis was performed using cellulose membranes with
a molecular weight cutoff of 3.5 kDa with water as solvent. 1H NMR spectra were
recorded at room temperature with a Varian INOVA 300 MHz spectrometer. In all cases,
the sample concentration was 10 mg/mL, and the appropriate deuterated solvent was used
as an internal standard. Dynamic Light Scattering was recorded with 90Plus particle size
analyzer (BIC). IR spectra were measured on Bruker FT-IR spectrometer (Bruker Optics
Inc, MA) using an attenuated reflectance attachment accessory. Fluorescent spectrum was
measured with FluoroMax-2 (ISA)

4.2.2 rTM Expression and Purification from E. coli
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rTM expression and purification were performed as the protocol in chapter IV.
Similar procedure was used for preparation of positive control protein His-rTM and rTM
without incorporation of azide group. Briefly, the expression plasmid TM456GGM was
transformed into E. coli BL21 (DE3) cells. For rTM with azide will be cultured and
expressed in M9 medium plus azidohomoalanine. While control rTM without azide
incorporation were grown in LB media and expressed in same conditions. rTM
purification and fusion tag removal were performed at the same conditions

4.2.3 Synthesis of Anchor Lipid DSPE-PEG3400-Triphenylphosphine (DSPEPEG3400-TP)
DSPE-PEG3400-NH2 (100mg, 35.8 µmol) was dissolved in 20 mL of CH2Cl2, and
0.2 mL of triethylamine was added. After stirring for 30 min at room temperature, a
solution of succinimidyl 3-diphenylphosphino-4-methoxycarbonylbenzoate (22 mg, 47.6
µmol) in 50 mL of CH2Cl2 was added. The reaction mixture was stirred at room
temperature for 24 hrs and then concentrated under vacuum to give a residue, which was
purified by silica gel chromatography with chloroform/methanol (4: 1, v/v) to afford
product 1 (41 mg, 9.0 µmol, 25 %). 1H NMR (CDCl3, 300 MHz) 8.06 (m, 1H), 7.79 (m,
1H), 7.44 (m, 1H), 7.66 (m, 2H), 7.52-7.42 (m, 2H), 7.28-7.34 (m, 8H), 6.64 (m, 1H),
5.19 (s, 1H), 4.34-4.20 (m, 3H), 3.95-3.80 (m, 3H), 3.80-3.50 (br. S, 44H, O-CH2-CH2O), 3.40-3.20 (m, 3H), 2.28 (br.s, 4H), 1.52 (br.s, 4H), 1.36-1.20 (s, 32H), 0.89 (t, J, 6.9 ,
6H), 31P NMR (CDCl3, 121 MHz) : -2.7.
4.2.4 Preparation of Triphenylphosphine Functionalized Liposome
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Triphenylphosphine functionalized liposome was prepared. DSPC and cholesterol
at 2:1 mol ratio were used as the major components of all liposome. 1 mol % of anchor
lipid DSPE-PEG3400-triphosphine was doped. In detail, the lipids mixture of cholesterol,
mPEG3400, DSPE-PEG3400-TP (2: 1: 5%: 1% molar ratio) were first dissolved in
chloroform. The solvent was gently removed on an evaporator under reduced pressure to
form a thin lipid film on the flask wall and kept in a vacuum chamber overnight. Then,
the lipid film was swelled in the dark with 2.5 mL PBS buffer (pH 7.4), followed 10
freeze-thaw cycles of quenching in liquid N2 and then immersed in a 50 °C water-bath to
form multilamellar vesicle suspension. Finally, the crude lipid suspension was extruded
through polycarbonate membranes (pore size 600, 200, and 100 nm, gradually) at a 60 °C
to afford small unilamelar vesicles.

4.2.5 Synthesis of rTM-Liposome Conjugates via Staudinger Ligation
rTM456-N3 (200 µg) was purified on a His-trap FF column and transferred into 50
mL of Tris-HCl buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4). The solution was
added into 2 mL of triphenylphosphine-functionalized liposome (DSPE-PEG3400-TP, 1%)
described above. The conjugation was then conducted at room temperature for up to 12
hrs with very gentle shaking under N2 atmosphere. The unreacted rTM456-N3 was
removed by gel filtration (1.5×20 cm column of Sephadex G-50) to generate rTM456liposome conjugate via Staudinger ligation DLS was used to monitor the integrity of the
vesicles during and after the coupling reaction.
4.2.6 Protein Assay by Bradford Method.
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1 mL purified rTM liposome conjugate from CL-6B column was collected in a
acetone compatible tube, followed by adding 4 mL cool acetone (-20 °C). The mixture
was votexed and incubates for 60 mins at -20 °C, followed by centrifuging 10 mins at
13,000-15,000 × g. Then, supernatant was removed carefully and not dislodge the protein
pellet. Next, the acetone was allowed to evaporate from the uncapped tube at room
temperature for 30 mins. 1 mL Tris-HCl buffer (20 mM, pH 7.4) was added for the
downstream process and vortexed thoroughly to dissolve protein pellet. Finally, the
protein assay was performed as instruction manual of Bradford protein assay (Bio-Rad).

4.2.7 Stability Evaluation of Liposome during Staudinger Ligation and Liposomal
rTM Conjugate
The stability of the liposomes during coupling reaction and the final liposomalrTM456 conjugate products were monitored by measuring fluorescent leakage in
comparison to the same type of liposomes unmodified having encapsulated selfquenching concentrations of 5,6-carboxyfluorescein (85 mM) using FluoroMax-2 (ISA,
NJ). Briefly, the lipid film composed of DSPC, cholesterol, mPEG2000, DSPE-PEG3400-TP
(2: 1: 5%: 1% molar ratio) was swelled in the dark with 2.5 mL Tris-HCl buffer (TrisHCl 20 mM, NaCl 150 mM, pH 7.4) containing 85 mM 5,6-Carboxyfluorescein (5,6-CF)
to form the multilamellar vesicle suspension. The crude lipid suspension was extruded
through polycarbonate membranes (Millipore sizes from 600 nm, 200 nm and 100 nm,
successively) to produce small unilamellar vesicles with an average mean diameter of
120 ± 10 nm, as judged by DLS. Separation of the CF vesicles from non-entrapped CF
was achieved by gel filtration chromatography, which involved passage through a 1.5×20
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cm column of Sephadex G-50. Twenty µL of reaction solution was taken and mixed with
1980 µL of Tris-HCl buffer (pH 7.4), and then the fluorescent intensity was measured by
using FluoroMax-2. A control experiment was conducted, in which recombinant TM
with azide group was replaced with recombinant TM without azide group in equal
amounts. To evaluate extent of fluorescence release upon disruption in the conjugation,
20 µL of 0.5 % Triton-100 solution was added into sample above to release all entrapped
CF molecules from the liposomes and fluorescence intensity was measured.
5, 6-carboxyfluorescein (CF) released from liposomes in PBS (pH 7.4) buffer at
room temperature was measured over time. The excitation and emission wavelengths of
5, 6-CF were 497 and 520 nm, respectively. The variation of the fluorescent intensity
with release time was calculated according to the equation below
Fraction of CF remaining in liposomes) = 1 - F/F0
where F is the fluorescent intensity measured at any time during the experiment and F 0 is
the total fluorescent intensity measured after disrupting liposomes completely with 0.5%
Triton X-100 in PBS (pH 7.4) buffer.

4.2.8 Catalytic Cofactor Activity Assay of Liposomal rTM by Protein C Activity
Assay
Catalytic cofactor activity assay of rTM derivatives including His-rTM456-N3,
rTM456-N3, and liposome-rTM456 Conjugates were analyzed by protein C assay. The
activity of recombinant TM456 was defined as moles of produced APC per min by given
amounts of rTM456 protein and rTM456 conjugates in the presence of thrombin. All
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activations of protein C by rTM conjugates were performed for 60 mins in 20 mM TrisHCl buffer, pH 7.4, 100 mM NaCl, 0.1% BSA, and 5 mM Ca2+ at 37°C. Typically, 20
nM thrombin and different rTM concentrations (1, 1.5, and 2 nM) were incubated in the
assay buffer. After 60 mins, 20 µL antithrombin III (3 µg/µL) and 20 µL heparin (1000
IU/mL) were added into the solution to stop the reaction. The inhibition of protein C
activation was completed within 5 mins at room temperature. The produced APC was
measured through hydrolysis of a chromogenic substrate (Spectrozyme PCa) by
comparing a standard curve, in which the concentration of APC to the rate of pnitroanilide (pNA) formation was measured. The hydrolysis of Spectrozyme PCa was
performed for 10 mins in the assay buffer at 37 °C, in which pNA was produced and the
concentration measured by monitoring at λ = 405 nm with a spectrophotometer.

4.3 Results and Discussion
4.3.1 Preparation of Triphenylphosphine Functionalized Liposome
The synthesis of triphenylphosphine functionalized liposomes starts with the
synthesis

of

anchor

lipid-DSPE-PEG3400-Triphenylphosphine.

First,

3-

diphenylphosphino-4-methoxycarbonylbenzoic acid NHS active ester was synthesized
according the procedure [12]; then the NHS active ester was reacted with commercially
available DSPE-PEG3400-NH2 to form triphenylphosphine functionalized anchor lipid by
amidation of primary amine in the lipid and NHS active ester (Figure 4.2). With the
anchor lipid in hand, small unilamellar vesicles composed of DSPC and cholesterol (2:1
mol ratio), 5% mPEG2000, 1.0 mol % of the anchor lipid in Tris-HCl buffer (20 mM, pH
7.4) were prepared by rapid extrusion through polycarbonate membrane with pore size of
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600, 200, and 100 nm diameter, sequentially at 65 °C. In the present study, mPEG2000
was used to improve stability of liposome in coupling reaction. This produced small
unilamellar vesicles show an average mean diameter of 12015 nm as determined by
dynamic light scattering.

Figure 4.2 Scheme for Synthesis of DSPE-PEG3400-Triphenylphosphine

4.3.2 Synthesis of rTM456-Liposome Conjugates via Staudinger Ligation
In order to make a membrane mimetic TM conjugate, we then investigated the
selective Staudinger ligation for conjugation of the rTM456-N3 onto triphenylphosphine
functionalized liposomes. Briefly, liposome incorporation of anchor lipid for Staudinger
ligation was prepared. Then, rTM456 was incubated with liposome for 12 hrs and
followed by purification through CL-6B column chromatography to provide liposomal
rTM456 conjugate. As In the present study, the chemically selective post-modification
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approach was investigated to generate the proposed rTM-liposome conjugate by taking
the advantage of the efficient utilization of rTM on the outer leaflet and avoiding
solubility problems in the formation of a lipid-protein conjugate. Furthermore, compared
to traditional direct liposome formulation for reagent delivery, the strategy used here
provides an opportunity to reduce inevitable loss of targets ligands when they are facing
the enclosed aqueous compartment and thus become unavailable for intended interaction.
Control experiment between rTM456 and liposome without anchor lipid was conducted
with the same procedure. As shown in figure 4.3, the reaction between rTM456 and
liposome with anchor lipid formed was observed as a new band after conjugation (Figure
4.3A), while control experiment between rTM456 and liposome without anchor lipid did
not exhibit any new bands (Figure 4.3B). These results indicated successful liposome
modification with rTM-N3 via Staudinger ligation.

Figure 4.3 Western Blot for Monitoring Conjugation by Staudinger Ligation. A: rTM-N3
with liposome including anchor lipid; B: rTM-N3 with liposome without anchor lipid
The conjugation efficiency of the click conjugation was evaluated by a given
amount of rTM456-N3 and fixed anchor lipid (DSPE-PEG3400-TP) concentration in the
liposome (1% of the lipids in liposome), in which DSPE-PEG3400-TP was in excess to
rTM456-N3. The grafted amount of rTM456-N3 onto the liposome was calculated after gel
filtration purification (CL 6B, GE Healthcare) by detecting unreacted rTM456-N3 in the
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buffer and rTM456-PEG3400-DSPE formed, respectively. Acetone was used to precipitate
proteins allowing for the physical separation of protein pellet from the liposomal solution.
The pellet was then redissolved in Tris-HCl buffer (pH 8.0) and detected by the Bradford
protein assay (Bio-Rad). As a result, the conjugation yield was 21% by detecting the
rTM-liposome conjugate formed and 30% by detecting the unreacted rTM-N3 left,
respectively. The gap between the calculated values of direct and indirect methods might
come from loss of unreacted rTM456-N3 during the process of purification for the indirect.

4.3.3 Stability Evaluation of Liposome during Staudinger Ligation and Liposomal
rTM Conjugate
Dynamic light scattering (DLS) was used to monitor the reaction and verify the
integrity of the liposome during and after the Staudinger ligation reaction. As shown in
Figure 4.4, there was no significant change in the size of the vesicles during and after
conjugation reaction. The average of liposome size increased from 112 ± 10 nm (Figure
4.4A) to 119 ± 15 nm (Figure 4.4B). After separation of the rTM-liposome conjugate
from the reaction solution, the rTM-liposome conjugate did not show size change (Figure
4.4C). Furthermore, there was no size change of control experiment in the presence of
rTM456 without azide group (Data not shown here). This result indicated that the
liposomes were intact during the reaction and purification processes.
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Figure 4.4 DLS Evaluation of Liposome Stability during Staudinger Ligation
Conjugation between Liposome with rTM456-N3: A. before conjugation; B. after
conjugation; C. purified conjugate
Fluorescent dye leakage of the same type of liposomes was conducted to further
test whether the conjugation could provoke leakage in the liposomes during the reaction
and the stability of liposomal conjugate. In present study, self-quenching concentrations
of 5,6-carboxyfluorescein (5,6-CF, 85 mM) was encapsulated into inner of liposome in
the preparation of liposome, then followed by passing through G-50 to remove free
fluorescent dye. The leakage of fluorescent day was monitored using FluoroMax-2 (ISA)
spectrometer. Based on the fluorescence quenching determinations in coupling reaction
(Figure 4.5A) and rTM-liposome conjugate releasing assay (Figure 4.5B), we
demonstrated that no apparent leakage was triggered by the conjugation reaction
compared to the liposomes incubated in the presence of rTM456 without azide group
(Data not shown here). This fluorescence intensity unchanging indicated that no liposome
disruption occurred during the conjugation even extension 24 hrs. In addition, the
conjugation of the rTM to the liposome surface may have enhanced the liposome stability
as it exhibited significantly slower dye release between 14 days to 25 days as compared
to the control liposome treated with rTM without azide (Figure 4.5B). These results
indicated the compatibility of the Staudinger ligation for rTM-liposome formation, and
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the rTM-liposome conjugate was quite stable and could be used for further activity
evaluation.
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Figure 4.5 Evaluation of Stability of Liposome during Staudinger Ligation Reaction (A)
and Stability of rTM-Liposome Conjugate (B) by Monitoring Fluorescent Dye 5,6-CF
Releasing from Liposomes. Disruption of liposomes (total in A and disruption in B) was
conducted by adding Tris-HCl buffer containing 0.5% Triton X-100 surfactant into the
liposome solutions.

4.3.4 Catalytic Activity Assay of rTM Conjugates
In this study, protein C activation activities of the rTM conjugates were evaluated.
The activity of rTM456 was defined as moles of produced activated protein C per min by
given amounts of rTM456 and rTM456 conjugates in the presence of thrombin. All protein
C activation assays by rTM456 and rTM456 conjugates were performed for 60 mins in a
buffer with 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% BSA, and 5 mM Ca2+ at 37 °C,
as previously reported [20]. The catalytic activity of rTM456 and rTM456 conjugates were
evaluated via the activation of varying human protein C concentration by rTM456 and
rTM456 conjugates in the presence of thrombin and calcium. The rate of protein C
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activation was linear with time until at least ~20% of the protein C was activated.
Reaction conditions (TM concentration or incubation time) were adjusted so that less
than 10 % of the protein C was activated to ensure that the amount of activated protein C
by TM was in the linear range. TM-phospholipid interactions have been widely
investigated before by different research group. The fact has been proven that
phospholipids play a positive effect on the enhancement of activation of protein C by the
thrombin-thrombomodulin complex in the surface of islet [21] or lipid vesicles [20, 22]
by physical incorporation. The activation of protein C by the thrombin-thrombomodulin
complex has comparable second-order rate constants by determination of the kinetic
parameters of activation of protein [23]. Therefore, it is the kcat/KM value that allows
direct comparison of the effectiveness of different forms of TM in different tissues or
organisms toward protein C. Typically, catalytic activity of TM will change by 1) altering
the kcat, 2) altering Km for protein C. As shown in the Table 4.1, recombinant His-TM456N3 and TM456-N3 do not have apparent loss of activity while after conjugation, the value
of kcat/KM of rTM-liposome conjugate has a twice to which of His-TM456-N3 or rTM456N3 although there was no apparent change of kcat, this change of kcat/KM mainly resulted
from decreasing of KM which is responsible for affinity of rTM for protein C. This result
was consistent with a previous report in which the enhancement of kcat/KM was from
increase of affinity of rTM for protein C [20]. This increasing of affinity may be the result
of using liposome as a platform which has a beneficiary effect on the configuration of the
conjugated rTM for enhancing thrombin and protein C binding.
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Table IV. Protein C Activation Activity of rTM and its Conjugate via Staudinger ligation

KM (μM)

kcat (min-1)

Full TM*

His-rTM-N3

rTM-N3

rTM-liposome

0.60±0.15

0.80±0.2

0.90±0.2

0.31±0.15

(0.90±0.2)

(1.0±0.5)

0.28±0.05

0.24±0.04

(0.22±0.05)

(0.16±0.05)

0.40±0.15

0.29±0.11

(0.26±0.1)

(0.16±0.05)

0.20±0.03

0.37±0.14

kcat/KM
(min-1.μM-1)

0.24±0.07

0.77±0.26

*commercial full TM of human, the data in parentheses are from Chaikof et at [18].

4.4 Conclusion
We demonstrated here the first example of biomimetic thrombomodulin
conjugates which were synthesized site-specifically at the C-terminal with a chemical tag
via Staudinger ligation. This liposomal rTM conjugate exhibited similar catalytic activity
of natural TM with a potential to develop a more forceful antithrombotic agent.
Furthermore, the proposed membrane-mimetic re-expression of recombinant TM onto
liposome will provide a rational design strategy for facilitating studies of membrane
protein functions and generating a protein-based drug
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CHAPTER V
SYNTHETIC BIO-INSPIRED THROMBOMODULIN CONJUGATES
VIA COPPER-FREE CLICK CHEMISTRY FOR EXPLORING
MEMBRANE PROTEIN’S SPECIFIC ACTIVITY

5.1 Introduction
TM is a glycoprotein that contains chondroitin sulfate glycosaminoglycans
(CSGAG) attached to the D3 domain, which contributes to TM’s thrombin binding,
stability, and plasminogen activation activities [1]. Synthetic glycopolymers with
multiple copies of sugar moieties have shown very promising results when used as
natural oligosaccharide mimics [2]. Glycoengineering aimed at adding carbohydrates to
proteins to alter pharmacokinetic properties, such as increasing in vivo activity and
prolonging the duration of action, has become a developing field in regards to the
enhancement of protein therapeutics [3, 4]. Recently, covalent attachments of synthetic
glycopolymers having multiple copies of sugar moieties have been explored for
therapeutic applications [5, 6]. Therefore, we hypothesized that modification of
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recombinant TM containing the EGF-like domains 456 (rTMEGF456) with glycopolymers
may mimic the natural glycosylation on the TM (Figure 5.1a) and that such modifications
may improve recombinant TM’s activity in vivo, such as reducing immunogenicity and
extending plasma half-lives.
Since TM is a membrane protein, it would be logical to develop a membrane
mimetic conjugate of TM to mimic the native endothelial antithrombotic mechanism
associated with cell membrane lipid components, thereby creating a more efficacious
agent than current soluble TM without the membrane domain [7]. In addition, liposomes
have been extensively studied as cell membrane models and as carriers for delivering
vaccines, enzymes, drugs, and genes to sites of action [8]. In this study, we envisioned
that rTM-liposome conjugates containing rTMEGF456 may provide a rational design
strategy for facilitating studies of membrane TM’s functions while generating an optimal
platform for exploring membrane protein-based drugs (Figure 5.1b).
In the past, the production of such protein-conjugates, to serve as effective
biotherapeutics, was hindered by nonspecific conjugation reactions, resulting in a variety
of isoforms, which potentially eliminate the protein’s proper activity for the intended use.
However, more advanced protein engineering and new bioconjugation techniques now
permit to include unique attachment sites within peptides for numerous applications in
protein engineering and functional studies. For example, the introduction of chemically
unique groups into proteins by means of non-natural amino acids allows for site-specific
functionalizations [9]. Previously, an azido-containing rTM construct was reported for
the site-specific conjugation with a methoxy-terminated polyethylene glycol (mPEG)
derivative via Staudinger ligation [10]. Site-specific immobilization of a rTM derivative
106

at the C-terminus through click chemistry with a suitably engineered alkyne PEG glass
slide was also demonstrated [7]. The Cu(I)-catalyzed click chemistry has become of
great use in modifying proteins and other macromolecules [6, 11]. However, a
disadvantage of this reaction is the potential presence of residual copper, which can be
potentially toxic, in the product intended for biological application [12]. Recently, to
avoid the use of the potentially toxic copper catalyst, copper-free click chemistry has
emerged as a popular bioorthogonal ligation strategy [13]. This reaction has been
employed to solve many problems in chemical biology, pharmaceutical science and
materials science. It has been used as a versatile chemistry for biomolecule modification
[14], cell surface modification [15] and biomaterial fabrication [16] applications. In this
study,

we

have

explored

regio-

and

chemoselective

glyco-

and

liposomal

functionalization of a recombinant TM456 derivative at the C-terminus through copperfree click chemistry in order to afford biomimetic TM conjugates, which are expected to
be potential anticoagulants with enhanced pharmacokinetic properties (Figure 5.1).
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Figure 5.1 Schematic Illustration of Syntheses of Biomimetic TM Conjugates: A. rTMglycopolymer conjugate; B. rTM-liposome conjugate via copper-free click chemistry
modifications. rTM456: recombinant TM containing EGF-like domains 4, 5, and 6.

5. 2 Experimental
5.2.1 Materials and Methods
All solvents and reagents were from commercial sources and were used as
received, unless otherwise noted. Deionized water was used as a solvent in all
experiments. The mouse monoclonal antibody specific to human TM was from
COVANCE Corp. (Richmond, CA). Purified recombinant human PC and human
thrombin were from Haematologic Technologies Inc. (Essex Junction, VT). Human antithrombin, recombinant human TM and chromogenic substrate Spectrozyme PCa were
from American Diagnostica Inc. (Stamford, CT). L-azidohomoalanine was from AnaSpec
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Inc. (Fremont, CA). 1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC), 1,2-disteroyl-snglycero-3-phosphoethanol-amine-N-[amino(polyethylene glycol)2000](ammonium salt)
(DSPE-PEG2000-NH2) were from Avanti Polar Lipids (Alabaster, AL). DBCO-PEG4-NH2
was from Click Chemistry Tools (Scottsdale, AZ). Glyco-Staining kits were from Geno
Technology

(St

Louis,

MO).

Cholesterol,

diphenylphosphino-4-methoxycarbonylbenzoic
sµlfonyl

chloride,

imidazole,

sodium

dicyclohexylcarbodiimide

acid,

azide,

hexaethylene

glycol,

N-hydroxsuccinimidobiotin,

(DCC),
toluene
N,N-

dimethylformamide and other chemicals were from Sigma-Aldrich (USA).
Mass spectrometry experiments were performed using QSTAR Elite mass
spectrometer (Applied Biosystems, Foster City, CA). Data was conducted with Analyst®
QS 2.0 software. Thin-layer chromatography (TLC) was performed on Whatman silica
gel aluminum backed plates of 250 μm thicknesses on which spots were visualized with
UV light or by charring the plate after dipping in 10% H2SO4 in methanol. Fluorescence
imaging of SDS-PAGE gels was performed using a Typhoon 9410 Variable Mode
Imager (Amersham Biosciences, USA). Dialysis was performed using cellulose
membranes with a molecular weight cutoff of 3.5 kDa with water as solvent. 1H NMR
and

13

C-NMR spectra were recorded at room temperature with a Varian INOVA 300

MHz spectrometer. In all cases, the sample concentration was 10 mg/mL, and the
appropriate deuterated solvent was used as an internal standard. Dynamic Light
Scattering was recorded with 90Plus particle size analyzer (BIC). IR spectra were
measured on Bruker FT-IR spectrometer (Bruker Optics Inc, MA) using an attenuated
reflectance attachment accessory. Fluorescent spectrum was measured with FluoroMax-2.
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5.2.2 rTM Expression in and Purification from E. coli.
rTM expression and purification were performed as the protocol in chapter IV.
Similar procedure was used for preparation of positive control protein His-rTM and rTM
without incorporation of azide group.

5.2.3 Synthesis of p-Amido[tetra(ethylene glycol)]-N-Dibenzylcyclooctynephenyl-βD-Galactopyranoside (DBCO-PEG4-CONH-Ph-Gal)
To a vial containing 3.2 mg of p-aminophenyl-β-D-galactopyranoside and a stir
bar, 0.1 mL Et3N was added and the reaction mixture was then allowed to stir for 15 min
at room temperature. After 15 min, then a 1 mL solution of dry DMF containing 9 mg
(1.1 eqv) DBCO-PEG4-NHS ester was added via syringe. The vial was then flushed with
N2 (g) and capped to stir at room temperature for 24 h. The reaction prior to work up was
checked by TLC 1:4 MeOH/CHCl3 against the starting materials to confirm reaction
completion. Then the solvent in the vial was reduced to near dryness under vacuum. The
residue was then chromatographed on silica gel using 1:4 MeOH/Chloroform solution as
eluent. The isolated compound, exhibiting long-wave UV-Vis fluorescence (Rf ~ 0.45,
1:4 MeOH/Chloroform), was collected and reduced to dryness achieving DBCO-PEG4CONH-phenylgalactose (4.7 mg, 47%). 1H NMR (CDCl3, 300 MHz) δ: 7.64 (d, 1H, HAr of DBCO), 7.46 – 7.34 (m, 12H, H-Ar of DBCO and Ph), 7.24 (d, 1H, H-Ar of
DBCO), 7.06 (d, 2H, H-Ph), 5.11 (d, 1H, H1-Gal), 4.84 (d, 2H, CH2 of DBCO), 3.92 (s,
1H, H-Gal), 3.80-3.47 (m, 5H, H-Gal), 3.55 (s, 16H, CH2-PEG), 3.23 (m, 1H), 3.09 (m,
1H), 2.92 (m, 1H), 2.60 (t, 4H, CH2COx2), 2.42 (m, 1H), 2.27 (m, 2H), 2.02 (m, 1H).
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FTIR (cm-1): 3341, 3066 (C≡C), 2875, 2486 (C≡C), 1715, 1646, 1508, 1456, 1397,
1226, 1076, 832.

5.2.4 Synthesis of DBCO-Functionalized Glycopolymer based on CyanoxylMediated Free Radical Polymerization
First, lactose-based O-cyanate chain-end functionalized glycopolymer was
synthesized from a lactose acrylamide derivative via cyanoxyl mediated free radical
polymerization. The procedure is described in detail in previously reported work [17].
Briefly, Sodium nitrite (7 mg, 1.0 mmol) and 4-chloroaniline (11 mg, 0.09 mmol) was
dissolved in 3ml mixture of H2O/THF (1:1, V/V), followed by adding HBF4 (122 mg, 1.5
mmol) to incubate for 30 mins. Next, acrylated lactose monomer (90 mg, 13 μmol)
NaOCN (27 mg, 0.42 mmol) and acryamide (105 mg, 13 μmol) was added sequently and
incubated over 16 h at 60 ℃, followed by dialysis (3500 Da, MW cutoff) to afford
lactose based O-Cyanate Chain-end gylcopolymer (275 mg, 65 %).
Then, DBCO Functionalized glycopolymer was synthesized directly from the
Lactose-based O-cyanate chain-end functionalized glycopolymer by dissolving 50 mg in
0.1 M sodium bicarbonate buffer (pH 8.3), and then by adding DBCO-PEG4-Amine (5
mg, 9.5 μmol) dissolved in 200 μL DMSO slowly. The mixture was allowed to stir for 12
h at room temperature, followed by dialysis (3500 Da, MW Cutoff) to remove any
unreacted DBCO-PEG4-Amine providing the DBCO functionalized glycopolymer (35
mg, 70%).
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5.2.5

Synthesis

of

1,2-Distearoyl-sn-glycero-3-phosphoethanol

amine-N-

[(Polyethylene glycol)2000]-N-[Tetra(ethylene glycol)]-N-Dibenzylcyclooctyne (DSPEPEG2000-DBCO)
To a dry 25 mL round bottom flask containing a stir a bar, DSPE-PEG2000-NH2
(94.4 mg, 0.034 mmol) was added and the flask was then equipped with a 3-way
stopcock and placed under vacuum for 20 min. The sealed flask, equipped with a balloon,
was backfilled with Ar(g) and then 3 mL of dry chloroform was added via syringe to
dissolve the contents under stirring. After the solid was dissolved, while stirring, DBCOPEG4-NHS ester dissolved in 1 mL of dry chloroform (20 mg, 0.029 mmols) was added
via syringe slowly, dropwise over 5 min, and the mixture was allowed to stir under Ar(g)
at room temperature for 15 min. Then, via syringe, triethylamine (0.05 mL, 0.36 mmols)
was added and the reaction was monitored via TLC (1:10 MeOH: CHCl3) over a 48 h
period.

After 48 h, or upon reaction completion, the reaction mixture was then

concentrated under reduced pressure and purified via silica gel column chromatography
using methanol/chloroform (1:10) as eluting solvent affording pure DSPE-PEG2000DBCO (0.077g, 79% yield).

1

H NMR (CDCl3, 300 MHz) δ: 8.06 (s, 3H), 7.68 – 6.6 (d,

8H), 5.21 (s, 1H), 5.13 (d, 2H), 4.35 (d, 2H), 4.21 (t, 2H), 3.99 (m, 6H), 3.73 – 3.55 (m,
204H), 3.10 (t, 1H), 2.70 (t, 2H), 2.47 (t, 2H), 2.29 (t, 4H), 1.59 (t, 4H), 1.35 (t, 4H), 1.26
(t, 52H), 0.88 (t, 6H).

13

C NMR (CDCl3, 75 MHz) δ: 173.4, 173.0, 136.1, 132.1, 129.1,

128.6, 127.8, 125.6, 108.0, 93.2 (alkyne), 70.6 (PEG), 67.2, 55.5, 45.7, 39.1, 36.8, 34.1,
32.0, 29.71, 24.9, 22.7. FTIR (cm-1): 3490, 2915, 2870, 2850, 2091, 1714, 1651, 1542,
1466, 1349, 1249, 1092, 948, 843, 720.
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5.2.6 Site-Specific Galactose-Modification of His-rTM456-N3 via Copper-Free Click
Chemistry
To 100 µL of 20 mM Tris-HCl buffer (pH 7.4) with 10 µg of recombinant HisTM456-N3, DBCO-PEG4-CONH-Phenyl-galactose (1 mg) in 20 µL DMSO was added,
and the mixture was stirred for 12 hrs at room temperature. SDS-PAGE gel (12%) was
used to separate the reaction mixture, followed by glyco-staining and Coomassie blue
staining to confirm reaction completion. Staining procedures were followed according to
the manufacturers’ instructions.

5.2.7 Site-Specific Glycopolymer-Modification of His-rTM456-N3 via Copper-Free
Click Chemistry
To 100 µL of 20 mM Tris-HCl buffer (pH 7.4) with 10 µg recombinant HisTM456-N3, DBCO-PEG4-Glycopolymer (2 mg) in 20 µL DMSO was added, and the
mixture was stirred for 12 h at room temperature. SDS-PAGE gel (12%) was used to
separate the reaction mixture, followed by glyco-staining and Coomassie blue staining to
confirm this reaction. Staining procedures were followed according to the manufacturers’
instructions.

5.2.8 Conjugation of His-rTM-N3 to Anchor Lipid (DSPE-PEG2000-DBCO) via
Copper-Free Click Chemistry
To a solution of 50 µg recombinant TM456 in 400 µL 20mM Tris-HCl buffer (pH
7.4), 0.5 mg DSPE-PEG2000-DBCO in 20 µL DMSO was added, and then the mixture
113

was stirred for 12hrs at room temperature. The efficiency of click conjugation between
anchor lipid and recombinant TM456 has been evaluated given amount of rTM456 and
anchor lipid over time. This conjugation was monitored by 12% SDS-PAGE gel and
visualization of protein bands by Coomassie blue staining. At the same time, western blot
was used to confirm the conjugate. Control experiment was conducted by incubation of
same amount of anchor lipid into rTM456 without azide group solution of Tris-HCl buffer.

5.2.9 Preparation of DBCO-Functionalized Liposomes
DSPC (15 mg, 20.43 µmol), cholesterol (4 mg, 10.2 µmol), mPEG2000-DSPE (4.6
mg, 1.67 µmol), DBCO-PEG2000-DSPE (2.2 mg, 0.65 mol) (2:1:5%:2% molar ratio) were
dissolved in 3.0 mL chloroform. The lipid mixture was dried onto the wall of a 100 mL
round-bottom flask by removing the solvent gently using a rotate evaporator under
reduced pressure followed by placing the vessel under vacuum overnight to form a thin
lipid film on the flask wall. Then the lipid film was swelled in the dark with 2.5 mL TrisHCl buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4) to form a multilamellar vesicle
suspension. Ten freeze-thaw cycles using liquid N2 followed by immersion in a 65 oC
water bath were performed. The crude lipid suspension was extruded through
polycarbonate membranes (Millipore size from 600 nm, 200 nm and 100 nm,
successively) to produce small unilamellar vesicles with an average mean diameter of
120 ± 10 nm, as determined by DLS.

5.2.10 Synthesis of rTM-Liposome Conjugates via Copper-free Click Chemistry
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His-rTM456-N3 (200 µg) was purified on a His-trap FF column and transferred
into 50 mL of Tris-HCl buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4). The solution
was added into 2 mL of DBCO-functionalized liposome (DBCO-PEG2000-DSPE, 2%)
described above. The click conjugation was then conducted at room temperature for up to
9 h with very gentle shaking. The unreacted His-rTM456-N3 was removed by gel filtration
(1.5×20 cm column of Sephadex G-50) to generate His-rTM456-liposome conjugate via
copper-free click chemistry. As in the same procedures above, the targeted rTM456liposome conjugate was synthesized by releasing the His tag of His-rTM456-N3 and
followed by treatment with DBCO-functionalized liposome (DBCO-PEG2000-DSPE, 1%)
prepared above in Tris-HCl buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4). DLS was
used to monitor the integrity of the vesicles during and after the coupling reaction.

5.2.11 Protein Assay by Bradford Method
1ml purified rTM liposome conjugate from CL-6B column was collected in a
acetone compatible tube, followed by adding 4ml cool acetone (-20 °C). The mixture was
votexed and incubates for 60 mins at -20 °C, followed by centrifuging 10 minutes at
13,000-15,000 × g. Then, supernatant was removed carefully and not dislodge the protein
pellet. Next, the acetone was allowed to evaporate from the uncapped tube at room
temperature for 30 mins. 1ml Tris-HCl buffer (20mM, pH 7.4) was added for the
downstream process and vortexed thoroughly to dissolve protein pellet. Finally, the
protein assay was performed as instruction manual of Bradford protein assay (Bio-Rad).
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5.2.12 Stability Evaluation of Liposome during Click Conjugation and Liposomal
rTM Conjugate
The stability of the liposomes during coupling reaction and the final liposomalrTM456 conjugate products were monitored by measuring fluorescent leakage in
comparison to the same type of liposomes unmodified having encapsulated selfquenching concentrations of 5,6-carboxyfluorescein (85 mM) using FluoroMax-2 (ISA,
NJ). Briefly, the lipid film composed of DSPC, cholesterol, mPEG2000-DSPE, DBCOPEG2000-DSPE (2:1:5%:2% molar ratio) was swelled in the dark with 2.5 mL Tris-HCl
buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4) containing 85 mM 5,6Carboxyfluorescein (5,6-CF) to form the multilamellar vesicle suspension. The crude
lipid suspension was extruded through polycarbonate membranes (Millipore sizes from
600 nm, 200 nm and 100 nm, successively) to produce small unilamellar vesicles with an
average mean diameter of 120 ± 10 nm, as judged by DLS. Separation of the CF vesicles
from non-entrapped CF was achieved by gel filtration chromatography, which involved
passage through a 1.5×20 cm column of Sephadex G-50. Copper free click conjugation
was conducted using the same procedure. Twenty µL of reaction solution was taken and
mixed with 1980 µL of Tris-HCl buffer (pH 7.4), and then the fluorescent intensity was
measured by using FluoroMax-2.

A control experiment was conducted, in which

recombinant TM with azide group was replaced with recombinant TM without azide
group in equal amounts. To evaluate extent of fluorescence release upon disruption in the
conjugation, 20 µL of 0.5 % Triton-100 solution was added into sample above to release
all entrapped CF molecules from the liposomes and fluorescence intensity was measured.
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5, 6-carboxyfluorescein (CF) released from liposomes in PBS (pH 7.4) buffer at
room temperature was measured over time. The excitation and emission wavelengths of
5, 6-CF were 497 and 520 nm, respectively. The variation of the fluorescent intensity
with release time was calculated according to the equation below
Fraction of CF remaining in liposomes) = 1 - F/F0
where F is the fluorescent intensity measured at any time during the experiment and F 0 is
the total fluorescent intensity measured after disrupting liposomes completely with 0.5%
Triton X-100 in PBS (pH 7.4) buffer.

5.2.13 Catalytic Cofactor Activity Assay of rTM Derivatives by Protein C Activity
Assay
Catalytic cofactor activity assay of rTM derivatives including His-rTM456-N3,
rTM456-N3, rTM456-Galactose, rTM456-glycopolymer and liposome-rTM456 Conjugates
were analyzed by protein C assay. The activity of recombinant TM456 was defined as
moles of produced APC per min by given amounts of rTM456 protein and rTM456
conjugates in the presence of thrombin. All activations of protein C by rTM conjugates
were performed for 60 mins in 20 mM Tris-HCl buffer, pH 7.4, 100 mM NaCl, 0.1%
BSA, and 5 mM Ca2+ at 37°C. Typically, 20 nM thrombin and different rTM
concentrations (1, 1.5, and 2 nM) were incubated in the assay buffer. After 60 mins,
20µL antithrombin III (3 µg/µL) and 20 µL heparin (1000 IU/mL) were added into the
solution to stop the reaction. The inhibition of protein C activation was completed within
5 min at room temperature. The produced APC was measured through hydrolysis of a
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chromogenic substrate (Spectrozyme PCa) by comparing a standard curve, in which the
concentration of APC to the rate of p-nitroanilide (pNA) formation was measured. The
hydrolysis of Spectrozyme PCa was performed for 10 min in the assay buffer at 37°C, in
which pNA was produced and the concentration measured by monitoring at λ = 405 nm
with a spectrophotometer.

5.3 Result and Discussion
5.3.1 Synthesis of DBCO-PEG4-CONH-Ph-Gal and Site-specific GalactoseModification of His-rTM456-N3 via Copper-Free Click Chemistry
The DBCO functionalized galactose was synthesized by reaction between NHS
activated DBCO and primary amine in the galactoses (Figure 5.2). The product was
characterized by 1H-NMR (Figure 5.3) and FTIR spectroscopy data (Figure 5.4). Finally,
Mass spectrometry was used to detect the molecule weight. The produce was
reconstituted in Solvent (50% acetonitrile, 50% water, and 0.1% formic acid) with
1.0µg/ml and load into ESI mass spectrometer by providing a peak at 850.23 (Figure 5.5),
which fits the calculated molecule weight (849.92)
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Figure 5.2 Scheme for Synthesis of DBCO-PEG4-CONH-Ph-Gal

Figure 5.3 1H NMR Spectrum (CD3OD/ D2O) of DBCO-PEG4-Phenyl-Galactose

Figure 5.4 FTIR Spectrum (cm-1) of DBCO-PEG4-Phenyl-Galactose
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Figure 5.5 Mass spectrum of DBCO-PEG4-Phenyl-Galactose
Modification of proteins with carbohydrates has become a developing field in the
enhancement of protein therapeutics [2, 18]. To test whether rTM456-azide could be
conjugated to a dibenzylcyclooctyne (DBCO) sugar derivative, our initial glycomodification of the protein via copper-free click chemistry was carried out with a DBCOcontaining galactose (DBCO-PEG4-CONH-Ph-β-Gal), followed by glyco-staining and
Coomassie blue staining to confirm the reaction product, respectively. rTM456 without an
azide group was used as a control for this experiment. The employment of the glyco-stain
for carbohydrate detection allowed for the detection of attached carbohydrate based on a
carbohydrate-specific periodic acid Schiff (PAS) staining method, in which the cis-diol
sugar groups were oxidized to aldehydes and then subsequently reacted with Schiff
reagent to yield a magenta band [19]. As shown in Figure 5.6, only the sample containing
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His-rTM456 with azide and DBCO-PEG4-CONH-Ph-β-Gal (Lane 1) exhibited a magenta
band whereas sample of His-rTM456 without azide and DBCO-PEG4-CONH-Ph-β-Gal
(Lane 2, positive control) and sample of His-rTM456 with azide and Phenyl-galactose
without DBCO (Lane 3, negative control) showed no glyco-staining.

Additionally,

Coomassie blue staining for all proteins in the gel did not exhibited any new bands, since
the molecular mass of the DBCO-PEG4-CONH-Ph-β-Gal is only 849 Da, too small to
alter protein migration pattern to be detected on SDS-PAGE. These results indicated the
successful modification of His-rTM456-azide with the galactose derivative via copper-free
click chemistry.

Figure 5.6 SDS-PAGE (12%) Characterization of Site Specific Glyco-Modification of
rTM via Copper Free Click Chemistry (pH 8.0, room temperature (RT), 6 hrs): A. Glycostaining, B. Coomassie blue staining: Lane 1: His-rTM-N3 treated with DBCO-PEG4CONH-Ph-β-Gal; Lane 2 : His-rTM treated with DBCO-PEG4-CONH-Ph-β-Gal; and
Lane 3: His-rTM-N3 treated with pNH2-Ph-Gal.
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5.3.2

Synthesis

of

DBCO-functionalized

Glycopolymer

and

Site-Specific

Glycopolymer-Modification of His-rTM456-N3 via Copper-Free Click Chemistry
Synthesis of DBCO-functionalized glycopolymer was conducted in two steps
(Figure 5.7). Fist, lactose-based O-cyanate chain-end functionalized glycopolymer was
synthesized from a lactose acrylamide derivative via cyanoxyl mediated free radical
polymerization in our lab [17]. Then the glycopolymer was incubated with DBCO-PEG4Amine in bicarbonate buffer (pH 8.3) for 12h at room temperature to provide the DBCO
functionalized glycopolymer with 70% yield. This product was characterized by 1H
NRM spectroscopy data (Figure 5.8).

Figure 5.7 Synthesis of DBCO-Functionalized Glycopolymer
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Figure 5.8 1H NMR Spectrum (CD3OD/D2O) of DBCO-Functionalized Glycopolymer
Next, a site-specific glycopolymer modification of the recombinant TM was
investigated using a DBCO-PEG4-Glycopolymer via copper-free click chemistry as
indicated above. SDS-PAGE was used to separate and identify the conjugate, followed by
glyco-staining and Coomassie blue staining, respectively. As shown in Figure 5.9, only
the sample including His-rTM456-N3 (with azide) (Lane 1) showed a magenta band of
high molecular weight (>130 kDa) while the His-rTM456 (without azide) treated with
DBCO-PEG4-Glycopolymer (Lane 2, positive control) and His-rTM456-N3 (with azide)
treated with glycopolymer without DBCO (Lane 3, negative control) exhibited no glycostaining (Figure 5.9A). Coomassie blue staining (Figure 5.9B) showed the same high
molecular weight band that appeared on the glyco-staining gel on Lane 1 containing His-
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rTM456-N3 (with azide) and DBCO-PEG4-Glycopolymer, and the protein band at ~51
kDa corresponding to unreacted His-rTM456 azide.

Figure 5.9 SDS-PAGE (12%) Characterization of Site-Specific GlycopolymerModification of rTM via Copper Free Click Chemistry (pH 8.0, RT, 6 hrs): A. Glycostaining, B. Coomassie blue staining: Lane 1: His-rTM-N3 treated with DBCO-PEG4Glycopolymer; Lane 2: His-rTM treated with DBCO-PEG4-Glycopolymer; and Lane 3:
His-rTM-N3 treated with glycopolymer (without DBCO).
The molecular weight achieved for the glycopolymer-protein conjugate was
higher than anticipated on the SDS-PAGE gel. This in part could be due to the fact that
the glycopolymer attached is a long chain molecule consisting of lactose and amide side
chains with very little charge, which may hamper the conjugate’s ability to move within
the electronic field during electrophoresis. This phenomena has been observed in
previous report when using glycopolymer to modify streptavidin [20]. Neither the
positive nor did the negative controls exhibit the formation of any new bands after
Coomassie blue staining. These results indicated successful glycopolymer modification
of the rTM456-N3 via copper-free click chemistry. Specifically, the reaction between two
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chain-ends of protein and glycopolymer facilitates the formation of uniform conjugate
with a point of attachment that is regio- and chemoselective.

5.3.3 Synthesis of Anchor Lipid (DSPE-PEG2000-DBCO) and Conjugation of HisrTM-N3 to Anchor Lipid via Copper-Free Click Chemistry
The anchor lipid with DBCO was synthesized by reaction between commercially
available NHS activated DBCO and lipid by forming stable amide bond with removing
NHS group (Figure 5.10). TLC plate was used to monitor the process. After 48h, there
was no more anchor lipid produced to confirm completion of this reaction. Finally, the
mixture was load into silica gel column chromatography to provide purified anchor lipid
by methanol/chloroform (1:10) as eluting solvent with 79% yield. The anchor lipid with
DBCO was characterized by 1H-NMR (Figure 5.11),
spectroscopy data (Figure 5.13).

Figure 5.10 Scheme for Synthesis of DSPE-PEG2000-DBCO
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13

C-NMR (5.12) and FTIR

Figure 5.11 1H NMR Spectrum (CD3OD/D2O) of DSPE-PEG2000-DBCO

Figure 5.12 13C-NMR Spectrum (CD3OD/D2O) of DSPE-PEG2000-DBCO
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Figure 5.13 FTIR Spectrum of DSPE-PEG2000-DBCO

With the anchor lipid (DSPE-PEG2000-DBCO) in hand, copper free click
conjugation of His-rTM456-N3 to anchor lipid was investigated to explore conjugation
condition. To a solution of recombinant His-TM456-N3, anchor lipid was added, and then
the mixture was stirred for 9hrs at room temperature. The efficiency of click conjugation
between anchor lipid and recombinant His-TM456-N3 was evaluated given amount of HisrTM456-N3 and anchor lipid over time. This conjugation was monitored by 12% SDSPAGE gel and visualization of protein bands by Coomassie blue staining. At the same
time, western blot was used to confirm the conjugate. Control positive control (HisrTM456-N3 and lipid without DBCO group) and negative control (His-rTM456 and anchor
lipid with DBCO group) were conducted in the same procedure was conducted by
incubation of same amount of anchor lipid into rTM456 without azide group solution of
Tris-HCl buffer. As result, a new broad band was observed in the conjugation while
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there was no any new band in the positive control and negative control experiment by
conducting His-rTM456 without azide group in its C terminal. According the SDS-PAGE
and Western Blot above, the conjugation was ended in 6 hours and there was no more
conjugate produced with continuously increasing incubation time to 9 hrs. Based on the
SDS-PAGE and Western blot (Figure 5.14), about 90% of rTM456 was modified by
anchor lipid by copper click conjugation.

Figure 5.14 SDS-PAGE and Western Blot for Monitoring Conjugation of His-rTM-Azide
with DSPE-PEG2000-DBCO (lipid anchor only)
5.3.4 Synthesis of Liposomal rTM456 Conjugates via Copper-Free Click Chemistry
In order to make a membrane mimetic TM conjugate, we then investigated the
selective click chemistry conjugation of the rTM456-N3 onto alkyne-PEG functionalized
liposomes. Conventional methods in the preparation of surface functionalized liposomes
involve the initial synthesis of the key lipid-ligand conjugate, followed by formulation of
the liposome with other lipid components. In this liposome formulation method, some of
the valuable ligands inevitably face the enclosed aqueous compartment and thus become
unavailable for their intended interaction with their target molecules. Therefore, in a
liposome formulation for reagent delivery, it is unrealistic if the targeting ligand is only
available in minimal amounts, which may hinder the ability of the carrier to reach its
destination and to properly interact with its target especially when multivalent binding is
necessary. Furthermore, lipid-ligand conjugates may have poor solubility and stability in
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aqueous solvent, or are incompatible with various manufacturing processes. In this study,
a chemically selective post-modification approach was investigated to generate the
proposed rTM-liposome conjugate. Briefly, liposomes bearing the anchor lipid DBCOPEG2000-DSPE were prepared, followed by incubation with His-rTM456-N3 in a Tris-HCl
buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4). The click conjugation was then
conducted at room temperature for up to 9 h under very gentle shaking. The unreacted
His-rTM456-N3 was then removed by gel filtration (1.5 x 20 cm column of Sephadex G-50)
to afford the targeted His-rTM456-liposome conjugate. SDS-PAGE and Western blotting
were used to monitor the conjugation progress. As shown in Figure 5.15 (A and B), the
His-rTM456-PEG2000-DSPE formed was observed as a new band after conjugation, while
neither the positive nor the negative control experiments exhibited any new bands. The
His-rTM456-PEG2000-DSPE conjugate was further confirmed by BaCl2/I2 staining which
visualizes the PEG molecules of the conjugate (Figure 5.15C), whereas both positive
(His-rTM456-N3 and liposome without anchor lipid, Figure 5.15D) and negative (HisrTM456 and liposome with anchor lipid, Figure 5.15E) control conjugations did not show
His-rTM456-PEG2000-DSPE conjugate formation. These results indicated successful
liposomal modification of the rTM-N3 via copper-free click chemistry. As in the same
procedures above, the targeted rTM456-liposome conjugate was synthesized by releasing
the His tag of His-rTM456-N3 and followed by treatment with liposomes bearing the
anchor lipid DBCO-PEG2000-DSPE in Tris-HCl buffer (Tris-HCl 20 mM, NaCl 150 mM,
pH 7.4). As shown in Figure 6.15F, Western blotting confirmed the new band formed
upon the rTM456-N3 reacted with the liposome.
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The conjugation efficiency of the click conjugation was evaluated by a given
amount of rTM456-N3 and fixed anchor lipid (DCBO-PEG2000-DSPE) concentration in the
liposome (2% of the lipids in liposome). The grafted amount of rTM456-N3 onto the
liposome was calculated after gel filtration purification (CL6B, GE Healthcare) by
detecting unreacted rTM456-N3 in the buffer and rTM456-PEG2000-DSPE formed,
respectively, in which DCBO-PEG2000-DSPE was in excess to rTM456-N3. Acetone was
used to precipitate proteins allowing for the physical separation of protein pellet from the
liposomal solution. The pellet was then redissolved in Tris-HCl buffer (pH 8.0) and
detected by the Bradford protein assay (Bio-Rad). As a result, the conjugation yield was
~60% by detecting the rTM-liposome conjugate formed and ~68% by detecting the
unreacted rTM456-N3 left, respectively.

Figure 5.15 SDS-PAGE (12%) Characterization of Site Specific Liposomal Modification
of His- rTM-N3 via Copper Free Click Chemistry (pH 8.0, RT): A. Coomassie blue
staining; B. Western blot; C. barium chloride/iodine staining; D. positive control: HisrTM456-N3 treat with liposome without anchor lipid; E. negative control: His-rTM456 and
liposome with anchor lipid DBCO-PEG2000-DSPE, F. Western blot for rTM456-N3 treated
with liposome with anchor lipid DBCO-PEG2000-DSPE
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5.3.5 Stability Evaluation of Liposome during Click Conjugation and Liposomal
rTM Conjugate
Dynamic light scattering (DLS) was used to monitor the reaction and verify the
integrity of the liposome during and after the click conjugation reaction. As shown in
Figure 5.16, there was no significant change in the size of the vesicles during and after
conjugation reaction. The average of liposome size increased from 118 ± 5 nm (Figure
5.16A) to 140 ± 5 nm (Figure 5.16B). After separation of the rTM-liposome conjugate
from the reaction solution, the rTM-liposome conjugate did not show size change (Figure
5.16C). Furthermore, there was no size change of control experiment (119 ± 10 nm) in
the presence of rTM456 without azide group (Figure 5.16D). This result indicated that the
liposomes were intact during the reaction and purification processes.

Figure 5.16 DLS monitoring of liposome stability during copper free click chemistry
conjugation between liposome (DBCO-PEG2000-DSPE, 2%) and rTM456-N3 (without Histag): A. before conjugation; B. after conjugation; C. purified rTM-liposome conjugate; D.
control: liposome (DBCO-PEG2000-DSPE, 2%) treated with rTM456 (without N3)
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To test whether the conjugation could provoke leakage in the liposomes during
the reaction and the stability of liposomal conjugate, fluorescent dye leakage of the same
type of liposomes having encapsulated self-quenching concentrations of 5,6carboxyfluorescein (5,6-CF, 85 mM) was monitored using FluoroMax-2 (ISA)
spectrometer. Based on the fluorescence quenching determinations (Figure 5.17A) and
rTM-liposome conjugate releasing assay (Figure 5.17B), we demonstrated that no
apparent leakage was triggered by the conjugation reaction compared to the liposomes
incubated in the presence of rTM456 without azide group. This fluorescence intensity
unchanging indicated that no liposome disruption occurred during the click conjugation
even after 12 h. In addition, the conjugation of the rTM to the liposome surface may have
enhanced the liposome stability as it exhibited significantly slower dye release between
14 to 21 days as compared to the control liposome treated with rTM without azide
(Figure 5.17B). These results indicated the compatibility of the copper-free click
chemistry for rTM-liposome formation, and the rTM-liposome conjugate was quite stable
and could be used for further activity evaluation

Figure 5.17 Evaluation of Stability of Liposome during Click Conjugation Reaction (A)
and Stability of rTM-Liposome Conjugate (B) by Monitoring Fluorescent Dye 5,6-CF
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Releasing from Liposomes. Disruption of liposomes was conducted by adding PBS
buffer containing 0.5% Triton X-100 surfactant into the liposome solutions.

5.3.6 Catalytic activity assay of rTM conjugates
In this study, protein C activation activities of the rTM conjugates were evaluated.
The activity of rTM456 was defined as moles of produced activated protein C per min by
given amounts of rTM456 and rTM456 conjugates in the presence of thrombin. All protein
C activation assays by rTM456 and rTM456 conjugates were performed for 60 mins in a
buffer with 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% BSA, and 5 mM Ca2+ at 37 °C,
as previously reported [21]. The catalytic activity of rTM456 and rTM456 conjugates were
evaluated via the activation of varying human protein C concentration by rTM456 and
rTM456 conjugates in the presence of thrombin and calcium. The rate of protein C
activation was linear with time until at least ~20% of the protein C was activated.
Reaction conditions (TM concentration or incubation time) were adjusted so that less
than 10% of the protein C was activated to ensure that the amount of activated protein C
by TM was in the linear range. As shown in Table 5.1, there was no activity change upon
glyco-modification of rTM456 with either galactose or lactose-containing glycopolymer.
However, rTM-liposome conjugates had a 2-fold higher kcat/KM value than that of either
His-TM456-N3 or rTM456-N3, even though there was no apparent change of kcat. This
change in kcat/KM mainly was due to a decreased Km value, which represents the affinity
of rTM for protein C. This result was consistent with a previous report of increased
kcat/KM values due to an higher affinity of rTM for protein C [22]. This increased affinity
may result from using liposome as a platform, which mimics endothelial cell lipid
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membrane and has a beneficiary effect on the conformation of the conjugated rTM for
enhancing thrombin and protein C binding.
Table V. Protein C Activation Activity of rTM and its Conjugates via Copper Free Click
Chemistry
rTMFull TM*

His-rTM-N3

rTM-N3

rTM-Gal

rTM-GP
liposome

KM (μM)

kcat (min-1)

0.60±0.15

0.20±0.03

0.37±0.14

kcat/KM
(min-1.μM-1)

0.80±0.2

0.90±0.2

(0.90±0.2)

(1.0±0.5)

0.28±0.05

0.24±0.04

(0.22±0.05)

(0.16±0.05)

0.40±0.15

0.29±0.11

(0.26±0.1)

(0.16±0.05)

0.95±0.22

0.87±0.15

0.33±0.17

0.22±0.12

0.18±0.17

0.23±0.17

0.25±0.14

0.18±0.11

0.71±0.32

*commercial full TM of human, Gal: galactose, GP: glycopolymer. The data in
parentheses are from Chaikof et at. [10]
5.4 Conclusion
We demonstrated here the first example of biomimetic TM conjugates that were
synthesized by site-specific conjugation of recombinant TM at the C-terminal with
glycopolymer and liposome via copper-free click chemistry. The protein conjugation
method presented here has distinct advantages over traditional methods. First, the sitespecific, chemo- and bio-orthogonal conjugation provides a simple and convenient route
to uniform protein conjugation in short time and good yields. Second, mild conjugation
conditions and low temperatures minimize the chance of protein denaturation. The rTMliposome conjugate showed a 2-fold higher kcat/KM value for protein C activation than
that of the rTM456, which indicated that the biomimetic lipid membrane has a beneficiary
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effect on the rTM’s activity. Continued studies of in vitro and in vivo antithrombotic
activity of these TM conjugates and their pharmacokinetic properties are under
investigation. Overall, the proposed glyco-engineering of recombinant TM with
glycopolymer and membrane-mimetic re-expression of recombinant TM onto liposome
provide a rational design strategy for facilitating studies of membrane glycoprotein TM
functions and generating a TM-based antithrombotic drug.
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CHAPTER VI
AZIDE-REACTIVE LIPOSOME FOR CHEMOSELECTIVE AND
BIOCOMPATIBLE LIPOSOME IMMOBILIZATION AND GLYCOLIPOSOMAL MICROARRAY FABRICATION
(Partial results are from Ma, Y., Zhang, H. L., Sun, X-L. Langmuir. 2011, 27, 1309713103 and Ma, Y., Zhang, H. L., Sun, X-L. Bioconjug. Chem. 2010, 21, 1994-1999)

6.1 Introduction
Immobilization of liposome onto solid surface has shown a great potential in
biological and biomedical research and applications [1]. This discipline has been inspired
by that liposome structurally retains the properties inherent in natural lipid membranes,
and functionally can serve as model of biomembrane and can encapsulate both
hydrophobic and hydrophilic compounds such as drug and gene for delivery applications
[2]. For example, immobilized liposomes have been investigated as model systems
presenting lipid membranes for bioseparation [3], biosensor [4], and nanobioreactor [5]
applications. Recently, immobilized liposomes onto a biomedical device have been
considered as a potential local drug delivery system, which release drug immediately to
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the environment surrounding the device, and reduce the toxic effects on other organisms
and thus enhance the therapeutic effect of the drug [6]. In addition, liposome microarray
has been explored recently for applications in membrane biophysics, biotechnology, and
colloid and interface science [7].
Surface-immobilized liposomes can be fabricated through either noncovalent such
as bio-affinity interaction or covalent bond formation by synthesizing anchor group
modified liposomes. Conventionally, the anchor group modified liposomes are prepared
by direct liposome formation method, in which the anchor lipid is synthesized first and
followed by formulation of the liposome with all other lipid components. In this direct
liposome formation method, however, some anchor-lipid conjugates may have limited
solubility and stability in solvent, or are incompatible with various stages of preparation,
or even may have difficulty to form liposome due to the loss of its amphiphilic property.
It is well known that the shape of the self-assembled liposomes may be influenced by the
nominal geometric parameters of its molecule such as polar head surface, tail volume and
chain length [8]. Alternatively, anchor group modified liposomes can be synthesized by
chemical modification of reactive preformed liposomes [9]. Variable successes using
amide [10] or thiol-maleimide coupling [11] as well as by imine [12] or hydrazine
linkage [13] have been reported. However, non-chemoselective, harsh reaction conditions
and low efficiency of most these methods limited their practical applications.
Azide-based ligation reactions have been expensively explored for highly
sensitive and biocompatible bioconjugation [14-16], polymer and materials science [17,
18] and drug discovery [19, 20]. Specifically, the azide is a versatile bioorthogonal
chemical reporter. Its small size and stability in physiological settings have enabled
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azide-functionalized metabolic precursors to hijack the biosynthetic pathways for
numerous biomolecules, including glycans [21], proteins [15, 22], lipids [23] and nucleic
acid-derived cofactors [24] and therefore can afford a variety of azide-containing
biomolecules for biomedical applications. Three reactions have been reported for tagging
azide-labeled biomolecules. One of these, the Staudinger ligation capitalizes on the
selective reactivity of phosphine and azide to form an amide bond [14, 25, 26]. The other
two involve the reaction of azide with alkyne to give triazole, a process that is typically
very slow under ambient conditions. The Cu(I)-catalyzed azide-alkyne cycloaddition also
known as "click chemistry", accelerates the reaction by use of a toxic copper catalyst [27,
28]. The copper may residue inside of the liposomes and thus cause problem in clinical
application. Recently, the strain-promoted [3 + 2] cycloaddition removes the requirement
for cytotoxic copper by employing cyclooctynes that are activated by ring strain [29, 30].
However, two triazole regioisomers forms during the conjugation, which affords
complicated products without controlling [31]. Most recently, we have demonstrated that
Staudinger ligation of triphenylphosphine-carrying liposome with azide-containing
biomolecules as a chemoselective liposome surface functionalization approach [32]. The
high specificity, high yield, biocompatible and the lack of residual copper reaction
condition natures of the Staudinger ligation approach make it an attractive alternative to
all currently used protocols for liposome surface functionalization. Herein, we
investigated expanded application of this azide reactive liposome for efficient and
chemical selective liposome surface immobilization and microarray fabrication
applications

(Figure

6.1).

Specifically,

microarray

of

liposome

carrying

triphenylphosphine onto azide-modified glass slide and further glyco-modification with
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azide-containing carbohydrate provides a cytomimetic glycoarray, which may find
important biomedical applications such as studying carbohydrate-protein interaction and
toxin and antibody screening and so on.

Figure 6.1 Illustration of Chemically Selective and Biocompatible Liposome Surface
Functionalization and Immobilization via Staudinger Ligation

6.2 Experimental
6.2.1 Materials and Methods
1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC), 1,2-disteroyl-sn-glycero-3phosphoethanolamine-N-[amino(polyethylene glycol)2000] (ammonium salt) (DSPEPEG2000),

1,2-disteroyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene

glycol)2000] (ammonium salt) (DSPE-PEG2000-biotin), 1,2-dipalmitoyl-sn-glycerol-3phosphoethanolmine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (DPPE-NBD) were purchased
from Avanti Polar Lipids (Alabaster, AL, USA). Cholesterol, dicyclohexylcarbodiimide
(DCC),

diphenylphosphino-4-methoxycarbonylbenzoic

acid,

hexaethylene

glycol,

toluene sulfonyl chloride, imidazole, sodium azide, N-hydroxsuccinimidobiotin, N,Ndimethylformamide were purchased from Sigma (USA). All other solvents and reagents
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were purchased from commercial sources and were used as received, unless otherwise
noted. Deionized water was used as a solvent in all experiments.
Instrumental analysis. Dynamic Light Scattering was measured with 90plus
particle size analyzer (Brookhaven Ins. Co., USA). Atomic force microscopes were
carried out using PicoPlus 3000 (Molecular Imaging, USA) and Fluorescence imaging
were obtained by Typhoon 9410 Variable Mode Imager (Amersham Biosciences, USA).

6.2.2. Synthesis of Anchor Lipid DSPE-PEG2000-Triphenylphosphine (1)
DSPE-PEG2000-NH2 (100 mg, 35.8 µmol) was dissolved in 20 mL of CH2Cl2, and
0.2 mL of triethylamine was added. After stirring for 30 min at room temperature, a
solution of succinimidyl 3-diphenylphosphino-4-methoxycarbonylbenzoate (33 mg, 71.6
µmol) in 50 mL of CH2Cl2 was added. The reaction mixture was stirred at room
temperature for 24 h and then concentrated under vacuum to give a residue, which was
purified by silica gel chromatography with chloroform/methanol (4:1, v/v) to afford
product 1 (32 mg, 28.5 %). 1H NMR (CDCl3, 300 MHz) 8.06 (m, 1H), 7.79 (m, 1H), 7.44
(m, 1H), 7.66 (m, 2H), 7.52-7.42 (m, 2H), 7.28-7.34 (m, 8H), 6.64 (m, 1H), 5.19 (s, 1H),
4.34-4.20 (m, 3H), 3.95-3.80 (m, 3H), 3.80-3.50 (br. S, 44H, O-CH2-CH2-O), 3.40-3.20
(m, 3H), 2.28 (br.s, 4H), 1.52 (br.s, 4H), 1.36-1.20 (s, 32H), 0.89 (t, J, 6.9 , 6H),
NMR (CDCl3, 121 MHz) : -2.7.

6.2.3. Synthesis of Azidoethyl-Tetra (ethylene glycol) Ethylamino Biotin (2)
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31

P

Triethylamine (0.03 mL, 0.02 mmol) was added to a solution of amino-11-azido3, 6, 9-trioxanundecane [20] (54 mg, 0.176 mmol) in DMF (3.5 mL). After the solution
was stirred for 30 min, a solution of N-hydroxsuccinimidobiotin (50 mg, 146 mmol) was
added. The reaction mixture was stirred for 12 h at room temperature and then
concentrated under vacuum to give a residue, which was purified by silica gel column
chromatography using acetone: hexane (4:1, v/v) as eluent to afford 2 (41 mg, 44%). 1H
NMR (CD3OD, 300 MHz) : 6.75 (br. S, 1H), 6.75 (br. S, 1H), 6.52 (br. S, 1H), 5.88 (br.
S, 1H), 4.51 (m, 1 H, -CH-1-Biotin), 4.32 (m, 1 H, -CH-4-Biotin), 3.70-3.63 (m, 16 H, O-(CH2CH2O)4-PEG), 3.56 (m, 2 H, -O-CH2CH2-N3), 3.39 (m 4 H, -CH2-NH and -OCH2CH2-N3), 3.24 (m 1 H, -CH-3-Biotin), 2.92 (dd, 1 H, J = 4.8, 12.8 Hz, -CH-2aBiotin), 2.71 (m 1 H, -CH-2b-Biotin), 2.23 (t, 1 H, J = 7.6 Hz, -CH2CO-Biotin), 1.761.63 (m, 4 H, -(CH2)2-Biotin), 1.50-1.40 (m, 2 H, -(CH2)-Biotin).

Figure 6.2 Scheme for Synthesis of Amino-11-Azido-3, 6, 9-Trioxaundecane
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6.2.4 Preparation of Biotin-Liposome via Staudinger Ligation
First, triphenylphosphine functionalized liposome was prepared. DSPC and
cholesterol at 2:1 mol ratio were used as the major components of all liposome. For
liposome biotinylation, 0.5 mol % of anchor lipid DSPE-PEG2000-triphosphine was
doped. To visualize the liposome immobilized onto the solid surface, all kinds of
liposome were incorporated with DPPE-NBD (0.5 mg, 0.6 mol %). In detail, the mixture
of lipids was first dissolved in chloroform. The solvent was gently removed on an
evaporator under reduced pressure to form a thin lipid film on the flask wall and kept in a
vacuum chamber overnight. Then, the lipid film was swelled in the dark with 2.5 mL
PBS buffer (pH 7.4), followed 10 freeze-thaw cycles of quenching in liquid N2 and then
immersed in a 50 oC water-bath to form multilamellar vesicle suspension. Finally, the
crude lipid suspension was extruded through polycarbonate membranes (pore size 600,
200, and 100 nm, gradually) at a 60 oC to afford small unilamelar vesicles.
Next, triphenylphosphine functionalized liposome incubated with biotin-PEG6azide to provide biotinylated liposome. In detail, to 2.5 mL of triphosphine-liposome in
PBS (pH 7.4) above, 1 mL of biotin-PEG6-azide (30 mg, 56 µmol) in PBS (pH 7.4) was
added; then the reaction mixture was incubated at room temperature for 6 h in an argon
atmosphere. The unreacted biotin-PEG6-azide was removed by gel filtration (1.5 × 20 cm
Column of Sephadex G-50). The size of liposomes during the Staudinger ligation was
monitored over time by using 90Plus particle analyzer.

6.2.5 Preparation of Biotin-Liposome via Direct Liposome Formation
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DSPC (43.2 mg, 54.7 µmol), cholesterol (10.6 mg, 27.4 µmol), DSPE-PEG2000Biotin (2.5 mg, 0.83 µmol) (2: 1: 1 % molar ratio) in 3 mL of chloroform. The solvent
was gently removed on an evaporator under reduced pressure to form a thin lipid film on
the flask wall and kept in a vacuum chamber overnight. Then, the lipid film was swelled
in the dark with 2.5 mL PBS buffer (pH 7.4), followed 10 freeze-thaw cycles of
quenching in liquid N2 and then immersed in a 50 oC water-bath to form multilamellar
vesicle suspension. Finally, the crude lipid suspension was extruded through
polycarbonate membranes (pore size 600, 200, and 100 nm, gradually) at a 60 oC to
afford small unilamelar vesicles.

6.2.6 Immobilization of Biotin-Liposome onto Streptavidin Glass Slide
Immobilization of the biotinylated liposomes above was performed by incubating
with streptavidin-glass slide (Xenopore Corp) in a 5 mg/mL of biotin-liposome
suspension (total lipid concentration) at room temperature for 4 hrs, followed by
removing the un-immobilized liposomes in the surface of glass slide. The glass slide was
washed by rinsing with PBS buffer for 1 hrs and then replacing with new buffer solution,
and repeated three times.

6.2.7 Liposome Array Based on Staudinger Ligation
The liposome prepared above was diluted to desired lipid concentration (2.0
mg/mL, total lipid concentration) by PBS (pH 7.4) buffer, then was printed onto azidePEG6-functionalized glass slide followed by incubating for 2.0 hrs at room temperature.
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Next, the liposome-immobilized glass slide was washed by rinsing with PBS (pH 7.4)
buffer for 2.0 hrs and repeated three times to remove unbound liposomes.

6.2.8 Staudinger Glyco-Functionalization of Immobilized Liposome
The liposome prepared above was printed onto azide-PEG6-functionalized glass
slide followed by incubating for 2.0 hrs at room temperature. Then the immobilized
liposome carrying triphenylphosphine was incubated with 2-azideethyl-lactoside in PBS
buffer (pH 7.4, 40 mg/mL) at room temperature for 2.0 hrs, followed by removing the
glass slide from the reaction solution. The glass slide was then washed by rinsing with
PBS (pH 7.4) buffer for 2.0 hrs and repeated three times.

6.2.9 Specific Lectin Binding onto Lactosylated Immobilized Liposome
The lactosylated liposome immobilized onto glass slide was incubated with lectin
(Arachis hypogae, FITC-labeled, Sigma) in PBS (pH 7.4) buffer solution (50 g/mL) at
room temperature for 2.0 hrs, followed by removing the glass slide from the reaction
solution. The glass slide was the washed by rinsing with PBS (pH 7.4) buffer for 2.0 hrs
and repeated three times

6.2.10 OG488 Labeling of rTM456
TM456 was labeled with OG488 succinimidyl ester as described with
modifications [33]. Briefly, to a solution of 150 μL of carbonate-bicarbonate buffer (pH
9.0), 50 μL of OG488 solution (10 mg/mL in DMSO) was added, followed by 150 μL
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aqueous TM456 solution (2 mg/mL). The mixture was gently vortexed at room
temperature in the dark for 2 hrs. After the coupling reaction, the unreacted OG488 was
removed by dialysis using centrifuge devices with a cutoff molecular weight of 10,000
Dalton.

6.2.11 rTM Conjugation to Immobilized Liposome by Staudinger Ligation
The liposome prepared above was printed onto azide-PEG6-functionalized glass
slide followed by incubating for 2.0 hrs at room temperature. Then, the immobilized
liposome carrying triphenylphosphine was incubated with rTM456 labeled by OG488 in
Tris-HCl buffer (pH 7.4, 0.5mg/mL) at room temperature for 2.0 hrs, followed by
removing the glass slide from the reaction solution. The glass slide was then washed by
rinsing with PBS (pH 7.4) buffer for 2.0 hrs and repeated three times. Fluorescence
imaging of glass slide was performed to explore whether rTM456 was conjugated to
immobilized liposome by using a Typhoon 9410 Variable Mode Imager (Amersham
Biosciences, USA).

6.2.12 Measurement of Releasing Kinetics of 5, 6-Carboxyfluorescein from
Liposome
5, 6-carboxyfluorescein (CF) released from free liposomes, immobilized
liposomes, and glycosylated immobilized liposomes in PBS (pH 7.4) buffer at room
temperature was measured over time. The excitation and emission wavelengths of 5, 6-
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CF were 497 and 520 nm, respectively. The variation of the fluorescent intensity with
release time was calculated according to the equation below
Fraction of CF remaining in liposomes) = 1 - F/F0
where F is the fluorescent intensity measured at any time during the experiment and F 0 is
the total fluorescent intensity measured after disrupting liposomes completely with 0.5%
Triton X-100 in PBS (pH 7.4) buffer.

6.3 Results and Discussion
6.3.1 Chemically Selective Liposome Biotinylation and Its Immobilization
Streptavidin/biotin-based liposome immobilization has been widely used by
synthesizing biotin-presenting liposome [34-36]. Conventionally, the biotin anchor group
modified liposome is synthesized by direct liposome formation method, in which the
biotin-lipid is mixed with all other lipid components to afford a liposome with biotin
oriented both outside and enclosed aqueous compartment. In the present study, we
explored azide reactive pre-prepared liposome carrying PEG-triphenylphosphine for
chemically selective liposome surface biotinylation through Staudinger ligation with
azide-containing biotin [Figure 6.3]. First, the terminal triphenylphosphine carrying
anchor lipid DSPE-PEG2000-triphenylphosphine 1 was synthesized by amidation of
commercially

available

DSPE-PEG2000-NH2

with

3-diphenylphosphino-4-

methoxycarbonylbenzoic acid NHS active ester synthesized as described in our previous
study [15]. Next, small unilamellar vesicles composed of phospholipids (DSPC) and
cholesterol (2:1 mol ratio) and 1.0 mol % of the anchor lipid 1 were prepared by rapid
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extrusion through polycarbonate membrane with pore size of 600, 200, and 100 nm
diameter, sequentially at 65 oC. This produced predominately small unilamellar vesicles
showed an average mean diameter of 120 ± 12 nm as judged by dynamic light scattering
(DLS) (Figure 6.3A). Finally, conjugation of azide-PEG6-biotin (2) to the preformed
liposomes was performed in PBS buffer (pH 7.4) at room temperature in an argon
atmosphere for 6 hrs. The azide-PEG6-biotin (2) was synthesized by amidation of amino11-azido-3,6, 9,trioxaundecane [16] with commercially available biotin NHS ester
(Sigma). DLS technique was used to verify the integrity of the vesicles during and after
the coupling reaction. As shown in Figure 6.3B, there is no significant size change of the
vesicles observed after biotinylation reaction. Therefore, the reaction condition above
does not alter the integrity of the liposomes and thus are harmless for liposome surface
modification.

Figure 6.3 Liposome Surface Biotinylation via Studinger Ligation
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Figure 6.4 DLS Monitoring of Size Change of Liposome before Biotinylation (A) and
after Biotinylation Reaction (B)

Next, streptavidin binding assay was examined to determine the success of the
biotinylation and whether the grafted biotin residues are easily accessible at the surface of
liposomes. It is well known that one streptavidin molecule is able to bind four biotin
molecules and the presence of streptavidin could induce aggregation of surface
biotinylated liposome. The biotin/streptavidin combination measurement was performed
by incubating streptavidin with the biotinylated liposome in PBS buffer (pH 7.4) at room
temperature. After 2 hrs, streptavidin-induced aggregation of the biotinylated liposomes
was confirmed by DLS (Figure 6.4A), while there was no aggregation observed for the
liposomes without biotinylation (Figure 6.4B). Furthermore, the presence of free biotin
(5.0 mM) prevented aggregates formation (not shown), confirming that the aggregation
was due to the specific recognition of the biotin residues on the surface of the liposome
by streptavidin. These results indicated that the liposome surface has been biotinylated
successfully and grafted biotin on the liposome surface was easily accessible. Similar
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result was obtained with the direct-formed biotin-liposome as positive control (Figure
6.5C).
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Figure 6.5 DLS Monitoring of Streptavidin Binding Assays of Biotinylated Liposomes:
Post Biotinylated Liposomes (A), Plain Liposomes without Biotin (B) and Direct
Biotinylated Liposomes (C)
Immobilization of the biotinylated liposome was performed by incubating with
streptavidin-coated glass slide (Xenopore Corp) in PBS buffer (pH 7.4) at room
temperature for 2 hrs followed by washing with PBS buffer (pH 7.4) three times. To
confirm the immobilized liposome on the glass slide surface, fluorescent imaging study
was examined with post biotinylated liposome and direct biotinylated liposome,
respectively. To visualize liposomes in the fluorescence image, DSPE-NTB was doped in
both liposomes as component for detecting by a microplate reader. As shown in Figure 4,
both post biotinylated liposome (Figure 6.6A) and direct biotinylated liposome (Figure
6.6B) yielded a uniform fluorescence image, while there was no apparent fluorescence
image observed for the nonbiotinylated liposomes (Figure 6.6C). Taken together, these
results indicated that the immobilization of intact liposomes was achieved with biotin
anchor.
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Figure 6.6 Fluorescence Image of Immobilized Liposomes onto Streptavidin-Coated
Glass Slides: Post biotinylated liposomes (A), Direct Biotinylated Liposomes (B) and
Plain Liposomes without Biotin (C) Doping with DSPE-NTB

To examine whether the immobilization reaction condition could provoke
liposome disruption, fluorescent dye releasing kinetics from the liposome during
immobilization reaction was investigated. Briefly, we have exposed our standard
conditions to the same type of liposomes but with encapsulated selfquenching
concentration (85 mM) of 5,6-CF. On the basis of the fluorescence quenching
determinations (Figure 6.7A), we could demonstrate that less than 7.2 % leakage of the
total loading was triggered during the immobilization reaction (2.0 hrs) compared with
5.2 % leakage for the same liposome during storage without reaction (2.0 hrs). The
leakage percentiles were calculated by destroying liposomes with surfactant 0.5 % Triton
X-100 in PBS (pH 7.4) buffer to release all 5,6-CF encapsulated after 2.0 h reaction.
These results indicated that the immobilization reaction condition is harmless for
liposome integrity. Continually, the subsequent fluorescent dye releasing kinetics over
time for the non-destroyed immobilized liposomes was examined to verify the stability of
the intact immobilized liposome in PBS (pH 7.4) buffer at room temperature. It was
found that immobilized liposome showed a constant leakage of approximately 25 %/day
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for three days (Figure 6.7B), whereas free liposome in PBS (pH 7.4) solution showed a
leakage rate of approximately 20 %/day (Figure 6.7C), which is slightly less than that of
immobilized liposome. The extended fluorescent dye releasing results further
demonstrated that intact liposomes had been successfully immobilized onto the glass
slide and showed sustained stability as well.

Figure 6.7 5,6-CF Releasing from Liposome during the Immobilization Reaction: before
Reaction, after Reaction, and after Adding 20 μL of 0.5 % Triton X-100 (A); the 5,6-CF
Releasing Kinetics from Immobilized Liposome (B); the 5,6-CF Releasing Kinetics from
Free Liposome (C); and the 5,6-CF Releasing Kinetics from Glycosylated Immobilized
Liposome (D) during Storage in PBS (pH 7.4) Buffer at rt during 0-72 hrs, and after
Adding 20 μL of 0.5 % Triton X-100 at the Final Point.
To provide further evidence that immobilized liposomes remain intact on the glass
slide surface, atomic force microscope (AFM) was used since it is a powerful tool for
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investigating surface-related physical and chemical properties in nanoscale. As shown in
Figure 6.8, typical AFM images of immobilized liposomes have been observed for post
biotinylated liposome (Figure 6.8A) and direct biotinylated liposome (Figure 6.8B) as
well, while there were no immobilized liposomes observed for the non-biotinylated
liposomes (Figure 6.8C). These results further confirmed the successful immobilization
of intact liposomes via biotin anchor.
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Figure 6.8 AFM Image Study of Immobilized Liposomes onto Streptavidin-Coated Glass
Slides: Post Biotinylated Liposomes (A), Direct Biotinylated Liposomes (B) and Plain
Liposomes without Biotin (C)

6.3.2 Chemically Selective Liposomal Microarray Fabrication
Liposome microarrays are versatile tools in biomedical research, as they can be
used for applications in membrane biophysics, biotechnology, and colloid and interface
science [7]. Most liposome microarrays were fabricated through bioaffinity between
anchoring group on the liposome surface and the counterpart group on the solid surface,
such as biotin/streptavidin7 and DNA hybridization [37]. In the current study, we
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explored chemically selective liposome microarray and its rTM conjugation performed
by the Staudinger ligation of a performed liposome carrying PEG-triphosphine with
azide-functionalized solid surface. The azid-PEG6-glass slide was used as model surface
for liposome microarray and was prepared by amidation of commercially available amine
glass slide (Xenopore, Co) with azido-PEG6-COO-NHS (Figure 6.9)

Figure 6.9 Scheme for Synthesis of Azido-PEG6-COO-NHS
In order to confirm the intact liposome immobilized on the glass slide surface,
fluorescence imaging study was conducted by doping DSPE-Rodamine (1 mol%, Avanti
Polar Lipid, Inc) in the liposome lipid bilayer so as to label lipid membrane and by
encapsulating 5,6-carboxyfluorescein (5,6-CF, Sigma) (50 mM) into the liposome so as
to image the inner compartment of the liposome. As results, either detecting 5,6-CF
(Figure 6.10A) or Rodamine (Figure 6.10B) yielded fluorescence image of the
immobilized liposome for azide-PEG glass slide treated with liposomes carrying anchor
group triphenylphosphine, while there was no apparent fluorescence image observed for
azide-PEG glass slide treated with liposomes without anchor group triphenylphosphine
(Figure 6.10C). These results indicated that the immobilization of intact liposomes was
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achieved through Staudinger ligation. Next, glyco-modification was performed by
incubation of the immobilized liposomes carrying thriphenylphosphine left over on the
liposome exterior surface with 2-azideethyl-lactoside [38] in PBS buffer (pH 7.4) at room
temperature under an argon atmosphere for 2 hrs. Specific lectin binding assay was
investigated to confirm the success of glycosylation and whether the grafted lactose
residues are easily accessible at the surface of the immobilized liposomes. The binding
assay was conducted by incubating lactosylated arrayed liposomes in the solution of galactose binding lectin (Arachis hypogae, 120 kDa, FITC-Labeled, Sigma) in PBS (pH
7.4) buffer at room temperature for 2.0 hrs, followed by washing with PBS (pH 7.4)
buffer three times. As shown in Figure 5, the specific binding of fluorescent labeled lectin
was observed on the lactosylated immobilized liposome spots (Figure 6.10E), while there
was no apparent fluorescence image observed for liposomes with anchor group
triphenylphosphine unmodilied (Figure 6.10D) and glycosylated liposome with lactose
pre-incubated lectin (Figure 6.10F) . These results indicated specific binding of lectin
onto the lactosylated arrayed liposomes.
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Figure 6.10 Fluorescence Images of Arrayed Liposomes: Selectively Exciting 5,6-CF
Encapsulated in the Liposome (A) and for Selectively Exciting PE-Rhodamine
Embedded in the Liposome Membrane (B), and Liposomes without Anchor Group
Triphenylphosphine (C); Fluorescence Image of Lectin (FITC-labeled Arachis hypogaea)
Binding onto the Arrayed Liposome: Liposomes with Anchor Group Triphenylphosphine
(D), Glycosylated Liposome (D), and Glycosylated Liposome with Lactose Pre-incubated
Lectin (E): Bar Size: 500 nm

6.3.3 rTM456 Conjugation to Immobilized Liposome by Staudinger Ligation
Next, liposome microarray and its rTM conjugation were designed as figure 6.11.
In the step I, immobilization of the preformed liposomes was performed by incubating
azide-PEG-glass slides with preformed liposomes in Tris-HCl buffer, followed by
addition of MeO-PEG2000-triphenylphosphine to quench the azide group left on the glass
slide. The unreacted liposomes were removed by washing with Tris-HCl buffer to afford
immobilized liposome. In the step II, glass slide with immobilized liposome was
incubated into OG488 labeled rTM456 for 2hrs at room temperature under argon
157

atmosphere, in which OG488 was use for identification of rTM modification by
providing fluorescence image. Positive control (liposome with anchor lipid incubated
with non-functionalized glass slide) and negative control (liposome without anchor lipid
with functionalized glass slide) experiments were performed at the same conditions. As
shown in Figure 6.12, only rTM conjugated liposome (Figure 6.12C) yielded a uniform
fluorescence, while positive control (non-functionalized glass slide) (Figure 6.12A) or
negative control (without anchor lipid in the liposome) (Figure 6.12B) did not show
apparent fluorescence image. Taken together, these results indicated that rTM
successfully conjugated to triphenylphosphine functionalized liposome to afford
liposomal rTM conjugate as mimics of natural TM.

Figure 6.11 Procedure for Liposome Immobilization and Its rTM Conjugation
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Figure 6.12 Fluorescent Image of rTM Conjugation to Immobilized Liposome: Positive
control (Non-functionalized Glass Slide) (A), Negative Control (without Anchor Lipid)
(B) and Immobilized Liposomal rTM Conjugate (C).

6.4 Conclusion
An azide reactive liposome has been developed for efficient and chemically
selective liposome surface modification and glyco-liposome microarray fabrication
applications. Specifically, microarray of liposome carrying triphenylphosphine onto
azide-modified glass slide and further glyco-modification with azide-containing
carbohydrate were demonstrated via Staudinger ligation. The high specificity and
efficiency and biocompatible reaction condition natures of this liposome biotinylation
approach make it an attractive alternative to all currently used protocols for liposome
surface functionalization. Notably, since there is no catalyst used in modification and
immobilization reaction, therefore, there is no concern of catalyst left in the resultant
liposome that is common problem in other liposome modification methods. The reported
method will provide a useful platform in the application of immobilized liposome system
for a variety of biomedical researches and practices.
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CHAPTER VII
SUMMARY AND FUTURE PROSPECT

7.1 Summary of Current Work
Cardiovascular diseases are still most like reasons for death in Unite States
although lots of attentions and efforts have been achieved to fight against them.
Antithrombotic agents that prevent blood clotting have been used for both the prevention
and treatment of active vascular thrombosis. However, current antithrombotic therapies
have met limited success due to the risk of series bleeding, hemorrhagic complication. In
present study, our goal of the proposed research is to develop recombinant
thrombomodulin (rTM)-based antithrombotic agents by synthesizing TM-liposome
conjugate that mimics the native endothelial TM’s antithrombotic mechanism. We
hypothesize that combination of antithrombotic membrane protein TM into lipid
membrane mimetic assembly (liposome) through recombinant and bioorthogonal
conjugation techniques provides a rational strategy for generating novel and potential
antithrombotic agent. The major accomplishments are briefly summarized below.
First, a chemo- and bio-orthogonal liposome surface functionalization through
Staudinger ligation reaction has been developed. Briefly, an unprotected carbohydrate
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derivative with an azide group was conjugated to the surface of vesicles presenting a
synthetic lipid carrying a terminal triphosophine function. The liposomes were kept
integrity during the reaction as measuring liposome size by dynamic light scattering
(DLS) and monitoring fluorescent dye releasing kinetics. Moreover, the successful
liposome surface functionalization was assessed by agglutination experiments using
lectin, which show that the grafted galactose residues were perfectly accessible on the
surface of liposome. This versatile approach, which is particularly suitable for the ligation
of water-soluble molecules and without catalyst, is anticipated to be useful in the
coupling of many other ligands onto liposome surface.
Second, to develop recombinant thrombomodulin (rTM)-based antithrombotic
agents that mimics the native endothelial TM’s antithrombotic mechanism, natural amino
acid-azidohomoalanine was successfully incorporated into TM at the C terminal by
directly acceptance of methionine analogs under help of Methionine-tRNA synthetases.
This incorporation of azidohomoalanine provides an azide moiety for site specific
conjugation through Staudinger ligation and Click chemistry, and makes an alternative to
explore protein interaction and the effect of cell membrane to integral protein by
membrane mimics.
Third, with azido-functionalized TM in hand, chemo-and bio-orthogonal methods
including Staudinger and Click chemistry have been explored to synthesize liposomal
rTM conjugate, respectively. In this study, protein C activation activities of the liposomal
rTM conjugates were evaluated. His-TM456-N3 and TM456-N3 do not have apparent loss of
activity while after conjugation, the value of kcat/KM of rTM-liposome conjugate has a
twice to which of His-TM456-N3 or rTM456-N3 although there was no apparent change of
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kcat, this change of kcat/KM mainly resulted from decreasing of KM which is responsible
for affinity of rTM for protein C. This result was consistent with a previous report in
which the enhancement of kcat/KM was from increase of affinity of rTM for protein C.
This increasing of affinity may be the result of using liposome as a platform which has a
beneficiary effect on the configuration of the conjugated rTM for enhancing thrombin
and protein C binding. Therefore, the proposed membrane-mimetic re-expression of
membrane protein domains onto liposome will provide a rational design strategy for
facilitating studies of membrane protein functions and generating a membrane proteinbased drug
In addition, the azide reactive liposome has been developed for efficient and
chemically selective liposome surface modification and glyco-liposome microarray
fabrication

applications.

Specifically,

microarray

of

liposome

carrying

triphenylphosphine onto azide-modified glass slide and further glyco-modification with
azide-containing carbohydrate were demonstrated via Staudinger ligation. The high
specificity and efficiency and biocompatible reaction condition natures of this liposome
biotinylation approach make it an attractive alternative to all currently used protocols for
liposome surface functionalization. Notably, since there is no catalyst used in
modification and immobilization reaction, therefore, there is no concern of catalyst left in
the resultant liposome that is common problem in other liposome modification methods.
The reported method will provide a useful platform in the application of immobilized
liposome system for a variety of biomedical researches and practices.
7.2 Future Prospects
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Although recombinant thrombomodulin (rTM)-based antithrombotic agents that
mimic the native endothelial TM’s antithrombotic mechanism have been successfully
developed via chemo-and bio-orthogonal methods including Staudinger and Click
chemistry, there still remain several prospects to explore before becoming an novel and
potential antithrombotic agent. Further investigation will seek to define the capacity of
the rTM-liposome to limit thrombus formation both in vitro and in vivo and to determine
their pharmacokinetics. The following researches are expected to be conducted
continually.

7.2.1 Evaluation of Anticoagulant Activity of rTM-Liposome Conjugates
Activated partial thromboplastin time (aPTT) and thrombin-clotting time (TT) are
common method to analysize coagulation disorder and first-order method to assay
anticoagulant therapy. Therefore, aPTT and TT should be performed to determine the
anticoagulant property of liposomal rTM conjugates.

7.2.2 Antithrombotic Activity Assay of rTM-Liposome
Evaluation of antithrombotic activity of TM in vivo is another important way to
demonstrate its efficacy and therapeutically promising application. A method for
antithrombotic activity assay by tissue factor-induced microthromboembolism in mice
should be investigated.

7.2.3 Measurement of the Circulating Half-life of rTM Liposome
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To remain appropriate drug retention time, namely circulation lifetime in vivo, is
very important to keep the maximum effect with minimizing the risk of toxicity. Lots of
novel drug candidates suffered from relatively short half-time and lose the opportunity to
develop a clinical drug. Particularly, to prolong life time is more challenging for protein
based drugs compared to traditional small drug molecules due to living system clearance
as well as enzymatic digestion. In the future, measurement of the circulating half-time of
rTM-liposome should be performed to assay the effect of liposome and PEG on half-time
of liposomal rTM conjugate. ELISA and functional APC assay can be performed to assay
half-time of liposomal rTM conjugate according to previous study.

169

